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Acetylation is an important post-translational modification (PTM). Lysine 
acetylation is a reversible PTM, where deacetylation is catalyzed by histone deacetylases 
(HDACs). Histone deacetylase function is crucial for a correctly functioning cell as 
aberrant acetylation, or deacetylation, has been linked to cancer, diabetes, 
neurodegeneration, and auto-immune disorders. Yet information about proper regulation 
of these enzymes is limited. Regulation of HDAC activity and selectivity has been 
proposed to include: the identity of the divalent active site metal ion, post-translational 
modifications, and protein interactions to form stable multi-protein complexes. HDAC 
activity and selectivity is further influenced by substrate amino acid sequence. This thesis 
explores how these different regulatory measures impact HDAC activity and selectivity.  
The biochemically well-characterized HDAC8 was used to investigate novel HDAC 
inhibitors and it was found that the identity of the active site divalent metal ion plays an 
important role in determining inhibitor selectivity. The identification and characterization 
of inhibitors with selective metal-binding groups, particularly Fe(II)-HDAC8 selective 
inhibitors, demonstrates structural differences between different HDAC8 metalloforms. 
This work also identified that the tropolone metal binding group potently inhibits HDAC8.  
To examine the impact of post-translational modifications and protein interactions 
on deacetylase activity and selectivity, a simplified CoREST complex including HDAC1 
was reconstituted. In vitro HDAC1 complex formation significantly increases deacetylase 
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activity (>10-fold) in comparison to HDAC1 in isolation. The presence of post-translational 
modifications, specifically phosphorylation, was found to impact substrate selectivity with 
the identification of a phosphorylation-specific acetylation site, without preventing 
complex formation.  
Finally, to explore the sequence-level substrate selectivity of HDAC6, we 
successfully constructed a structure-based model of the catalytic domain of HDAC6.  This 
model was used to predict novel substrates that were then validated using peptide 
mimics.  These data demonstrated that the substrate selectivity of HDAC6 is more 
promiscuous than HDAC8. The comparison of the activity of the single catalytic domain 
of HDAC6 with HDAC6 containing both catalytic domains demonstrates that the different 
structural components influence the activity and substrate selectivity profile of the 
enzyme.  
The findings discussed within this thesis illustrate several regulatory factors impart 
a sizeable contribution to deacetylase activity and selectivity. Such factors include 
structural components, including cofactors and post-translational modifications, in 
addition to protein interactions. The contribution of this thesis to the growing knowledge 
of how HDACs are regulated provides insight into the enzymes’ biological function to lead 
to the development of more effective therapeutic interventions.  
 
1 
Chapter 1 : Introduction 
 
Post-translational modifications (PTMs) of proteins, first identified 60 years ago, 
have been found to be widespread across the proteome. The first PTM discovered was 
phosphorylation[1], closely followed by acetylation. Protein acetylation, specifically on 
lysine residues, was discovered on histone tails in 1963[2, 3]. In the following two 
decades, numerous other acetylated proteins were found such as tubulin[4] and p53[5]. 
However, until mass spectrometry was able to be effectively used in a high-throughput 
manner to identify acetylation, acetylated proteins were thought to be limited and focused 
to the nucleus. Today, there are thousands of acetylation sites identified throughout the 
cell[6].  
Acetylation is a reversible PTM, thus it can act as a regulatory switch. On histones, 
acetylation, catalyzed by histone (or lysine) acetyltransferases, generally promotes 
transcription and deacetylation, catalyzed by histone deacetylases, generally represses 
transcription[7, 8]. It took 30 years after the discovery of acetylation before the enzymes 
responsible were isolated and purified. Acetyltransferases and deacetylases were first 
isolated in yeast and protozoans[9]. Using the knowledge garnered from yeast, an 
inhibitor capture method was used to isolate the first human deacetylase, histone 
deacetylase 1 (HDAC1)[10, 11]. The purified HDAC1 demonstrated in vitro deacetylase 
activity against histones, earning its name. Discovery of more deacetylases happened 
rapidly thereafter[12-19].   
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The histone deacetylase family is divided into four classes based on homology to 
yeast deacetylases. Classes I, II, and IV, referred to as HDACs, are metal-dependent 
deacetylases, requiring a divalent metal for catalysis within a conserved catalytic domain. 
Class III enzymes, named sirtuins based on their homology to the yeast enzyme, Sir2, 
utilize a NAD-dependent mechanism. Herein, only the metal-dependent deacetylases, or 
HDACs, will be discussed in detail (Figure 1.1). Class I includes HDAC1, HDAC2, 
HDAC3, and HDAC8. All are homologous to yeast deacetylase, Rpd3. The Class II 
HDACs: 4, 5, 6, 7, 9, and 10, are homologous to another yeast deacetylase, HdaI. Class 
II is further divided into Class IIa and Class IIb, based on sequence homology. Class IIa 
consists of HDAC4, HDAC5, HDAC7, and HDAC9. Class IIb consists of HDAC6 and 
HDAC10, where HDAC6 uniquely contains a second deacetylase domain.  
 
Figure 1.1: The classes of histone deacetylases and their domain components. 
All HDACs contain a conserved active site. The active site consists of a His-Asp-
Asp metal binding site at the end of an internal cavity that accommodates the lysine side 
chain. The catalytic mechanism has recently been determined to be most consistent with 
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an active site conserved histidine serving as a single general base-general acid to 
activate the metal-water nucleophile and then protonate the lysine leaving group (Figure 
1.2) [20].  
 
Figure 1.2: Catalytic mechanism of histone deacetylases 
HDACs demonstrate varied catalytic efficiency. The Class I enzymes demonstrate 
the greatest in vitro deacetylase activity, apart from HDAC8. HDAC8 has been measured 
to be ~1000 times less active than HDACs 1-3[21]. HDAC6 demonstrates high catalytic 
activity similar to HDACs 1-3[21]. Whereas the activity of HDAC10 has been measured 
to be close to that of HDAC8[21]. Recently, HDAC10 was shown to more efficiently 
deacetylate polyamines than acetyl-lysine peptides[22]. The Class IIa enzymes are the 
only members proposed to lack catalytic activity. All other HDACs contain a conserved 
tyrosine in the active site which forms hydrogen bonds with the substrate’s acetyl group 
(Figure 1.2). HDACs 4,5,7,and 9 have an amino acid substitution of the tyrosine to a 
histidine abolishing deacetylase activity[23]. The Class IIa enzymes have rather been 
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found to influence deacetylation through protein interactions[24]. Lastly, HDAC11 
demonstrates little in vitro deacetylase activity. HDAC11 has been shown to more 
efficiently catalyze deacylation of fatty-acids[25, 26]. The variation of catalytic activity 
amongst the HDAC enzymes alludes to functional differences. 
HDACs are considered to be ubiquitously expressed. Cellular localization of 
HDACs varies by class. It is widely believed Class I and IV are primarily found in the 
nucleus, however HDAC8 has been found in the cytoplasm of smooth muscle cells[27-
29], indicating potential tissue-specific variability. Class IIa shuttles in and out of the 
nucleus depending on post-translational modifications and protein interactions[30-32]. 
Class IIb are primarily cytoplasmic[33], though HDAC6 has also been found in the nucleus 
and contains a nuclear localization signal and two nuclear export signals[34, 35]. Any 
regulatory mechanism of HDAC6 localization is unknown.  
Though we understand the mechanistic activity of HDACs, the specific biological 
activity of each enzyme is unclear. All the HDAC enzymes appear to regulate 
transcription[15, 18, 33, 36-39]. HDACs further regulate the immune response through 
their involvement in cytokine gene transcription and development of regulatory T-cells[40-
45]. Specifically, Class I HDACs are involved in the cell cycle: controlling cell growth[46, 
47], proliferation[48-51], differentiation[52, 53], and apoptosis[47, 54, 55]. Class IIa 
enzymes regulate development and cellular differentiation[56]. Class IIb enzymes play a 
role in cell proliferation, specifically, HDAC6 activity has been linked to the cellular 
processes of cell motility[57-59] and autophagy[60-62].   
Aberrant HDAC function has been implicated in numerous diseases. Mis-
regulation of acetylation has been connected to cancer[63], neurological diseases 
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including Alzheimer’s[64-66], and immune disorders[67]. The potential role of HDACs in 
the onset of these disorders has led to a large amount of research into HDAC inhibition. 
There are currently four FDA-approved inhibitors of Class I HDACs for use in treatment 
of T-cell lymphoma and multiple myeloma[63] (Figure 1.4, denoted with an asterisk). 
These four inhibitors are not enzyme-selective and have a deleterious effect on the health 
of the patient[63]. Novel inhibitor research has become a focus of the HDAC field due to 
the clinical potential but many clinical results of new inhibitors, both selective and non-
selective, have been disappointing[63, 68].  
Inhibitor Development 
 The previously developed inhibitors generally have a consistent structure: zinc 
binding group (ZBG) – linker – cap. The divalent active site metal allows development of 
inhibitors with a metal-binding group to displace the metal-bound water nucleophile 
(Figure 1.3). The linker region mimics the lysine side chain to fill the internal substrate 
binding tunnel. The cap group enhances binding to the enzyme by forming additional 
contacts on the outer protein surface.  
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Figure 1.3: Crystal structures of HDACs with inhibitors bound.  
Inhibitor structures are given in Figure 1.4. A) HDAC2 complexed with vorinostat (PDB 4lxz). B) HDAC8 
complexed with a selective hydroxamic acid inhibitor 1 (PDB 5fcw). C) HDAC4 complexed with a selective 
carboxamide inhibitor 2 (PDB 4cbt). D) HDAC6 complexed with selective inhibitor ACY-1083 (PDB 
5WGM).  
 
Hydroxamates are the most used ZBG due to their potent metal binding affinity. 
However, the hydroxamate moiety has poor pharmacokinetics due to its reactivity and is 
not stable in vivo for more than an hour[69]. There are other groups used as ZBGs, 
including benzamide, carboxylic acids, thiols, and trifluoroketones[70] (Figure 1.4-A). 
However, these moieties have been unable to match the potency of the hydroxamate, 
with a few exceptions. Research has begun to focus on discovery of novel ZBGs.  
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Figure 1.4: Inhibitor structures 
The zinc binding group is shown in red, the linker in black, and the cap group in red. (A) Examples of 
HDAC inhibitors containing traditional zinc binding groups. (B) Examples of HDAC inhibitors containing 
novel zinc binding groups. (C) Examples of isozyme selective HDAC inhibitors. 
 
There have been numerous attempts to discover novel non-hydroxamate ZBGs. 
Numerous chemical groups have been used as ZBGs to develop both selective and non-
selective HDAC inhibitors. These groups include hydroxypyrimidines, hydrazides, 
triazolylphenyls, tropolones, sulfonamides, and carboxamides[63, 71-74] (Figure 1.4-B). 
The work into novel ZBGs is encouraging for developing inhibitors with better 
pharmacokinetics. Though, the overall focus of inhibitor development is still on the 
traditional ZBGs, with most patents filed from 2012-2017 containing hydroxamates or 
benzamides, and very few containing a novel ZBG[68].  
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There is an additional focus on development of isozyme selective HDAC inhibitors 
with the goal of maintaining biological activity while decreasing toxicity. Crystal structures 
and molecular docking studies have provided insight into the development of these 
selective inhibitors. Though all HDACs utilize the same catalytic mechanism, there are 
enough structure differences between the enzymes to allow for selective binding. HDAC6 
has been an exceptional hotspot for inhibitor development with numerous inhibitors 
developed based on the structure of tubastatin, which contains a hydroxamate ZBG and 
a large aryl, cap group. Selectivity for HDAC6 seems to be determined by this large 
hydrophobic, cap group[72]. Selective inhibitors for Class I enzymes utilize structural 
elements that interact close to the active site and within the internal cavity[72]. PCI-34051, 
an HDAC8 inhibitor, is an example of a unique linker structure enabling selectivity[75]. 
RGFP966, a HDAC3 inhibitor, demonstrates the importance of a modified ZBG structure 
conferring selectivity[76]. Lastly, several selective inhibitors have been developed for 
Class IIa HDACs. These selective inhibitors contain bulkier aromatic groups around the 
hydroxamate ZBG instead of a leaner linker[72]. These bulkier groups interact with 
hydrophobic pockets near the active site to provide for Class IIa inhibitor selectivity[73].  
HDAC inhibitor development shows promise for clinical treatment of multiple 
diseases. However, there is a lack of understanding of the biological pathways such 
inhibitors would affect. This chapter will summarize the current understanding of biological 
activity of HDACs and how that activity is regulated.  
Importance of Protein-Protein Interactions 
 Many HDAC do not function alone, rather they form both stable and transient 
interactions with other proteins. BioGRID, the Biological General Repository for 
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Interaction Datasets, lists almost 3,000 protein interacting partners for the 11 HDACs[77]. 
Almost half of those protein interactions are connected to HDAC1 and 2 (Figure 1.5-A-
D)[77]. In 2013, the most comprehensive study was performed to map the interactome of 
the HDAC family[78]. This study determined interactions in T-cells by immunoprecipitation 
of the GFP-tagged HDACs followed by protein identification using mass spectrometry[78]. 
While the study has some limitations, including only one cell type was analyzed and the 
use of a bulky GFP tag could prevent some interactions, it does demonstrate the  
extensive network of HDAC-protein interactions related to numerous biological 
processes, including many previously unknown interactions[78].  
Protein interactions with HDAC1, 2, and 3 are proposed to be necessary for 
activity. When purified to homogeneity these isozymes have little to no deacetylase 
activity[79]. HDAC1, 2, and 3 function in stable nuclear complexes (Figure 1.5-E). 
HDAC1 and HDAC2 are found within 3 complexes: Sin3, NuRD, and CoREST[80]. 
HDAC3 associates with nuclear receptor repressors, SMRT and NCoR[79]. Unlike its 
Class I counterparts, HDAC8 is catalytically active in vitro in a purified, isolated state and 
does not require any binding partners for deacetylase activity[15]. This is most likely not 
the case in vivo as immunoprecipitated HDAC8 contained several proteins, including 
proteins involved with the cell cycle and protein transport[78]. The interaction network for 
HDAC8 is not as extensive as HDAC1, 2, and 3, where there are far more interactions 
with proteins related to gene expression[78]. The T-cell study did reveal some interesting 
new HDAC1 interactions involved in protein transport and metabolism[78].    
 The Class IIa enzymes, as they are catalytically inactive, derive all their function 
from protein interactions. Interaction with 14-3-3 signaling proteins controls nuclear 
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localization of the Class IIa enzymes, which in turn controls their ability to interact with 
MEF2 transcription factors to repress transcription[30, 32, 56, 81]. Class IIa enzymes also 
interact with the HDAC3/SMRT/NCoR complex[24]. The interaction network found in T-
cells between HDAC4, 5, and 7 was found to be rather redundant and predictable 
between the isozymes as only known interactions were identified[78]. The remaining 
Class IIa enzyme, HDAC9 demonstrated a distinctly different interaction network with 
novel interactions identified with proteins related to gene expression, the cell cycle, and 
RNA processing[78].    
 
Figure 1.5: Interaction networks of Class I HDACs 
Obtained from BioGRID[77, 82]. (A) HDAC1. (B) HDAC2. (C) HDAC3. (D) HDAC8. (E) Composition of 
stable nuclear complexes of Class I HDACs 
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HDAC6 is known to have protein-protein interactions that are more transient in 
comparison to the stable Class I complexes. HDAC6 uniquely contains a zinc finger, 
ubiquitin binding domain with high affinity for ubiquitinated proteins[83]. HDAC6 uses this 
domain to function as a linker between aggregated protein and the motor protein dynein, 
to facilitate the aggregate’s transport to the aggresome[60]. Additionally, a complex 
containing HDAC6, HDAC11, and HDAC2 has been proposed at the vitamin D receptor 
involved in the regulation of transcription factor, MYC[84]. The HDAC6 interaction network 
consisted of previously unidentified interactions with proteins involved in ubiquination, 
RNA processing, the cell cycle, gene expression, protein transport, and metabolism[78]. 
A limited interaction network was found for HDAC10[78].  
While not much is known about HDAC11, immunoprecipitation of the isozyme 
revealed an astonishing 124 interacting proteins, a select number of which were validated 
by further co-immunoprecipitation experiments[78]. The identified proteins are involved in 
diverse biological processes: gene expression, the cell cycle, RNA processing, 
ubiquitination, signal transduction, protein transport, protein folding, and metabolism[78]. 
Additional studies to explore these potential interactions could reveal extensive 
functionality of HDAC11.     
It is apparent HDAC enzymes function within a network of protein interactions. 
These interactions no doubt affect HDAC catalytic activity and substrate selectivity. 
Substrate Discovery 
 In 2009, immunoaffinity enrichment of acetylated peptides coupled to high-
resolution mass spectrometry identified thousands of acetylation sites across the 
proteome[85]. In the 11 years since that study the number of acetylated proteins and 
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acetylation sites has only grown. PhosphoSitePlus, a database of post-translational 
modifications, indicates ~38,000 acetylation sites on ~20,000 proteins have been 
identified by high-throughput and low-throughput analyses[6]. Many validated acetylated 
proteins have been linked to sirtuins as the deacetylation enzyme. However, selective 
sitruin inhibitors are available to determine enzyme-specific function in contrast to 
unselective pan-HDAC inhibitors which could contribute to this finding. Despite this, there 
have been a limited number of acetylation sites where deacetylation is attributed to 
specific HDACs.  
The identification of an acetylated protein as a substrate of a HDAC is traditionally 
determined by a few common methods. Potential substrates can be identified by in cellulo 
deacetylase inhibition, transient transfection to over-express a HDAC isozyme, and/or 
knockdown of HDAC expression using siRNA. The effectiveness of these methods can 
be debated. The lack of isozyme-specific inhibitors limits the detection of isozyme-specific 
substrates. The functional redundancy of the isozymes could also limit the effectiveness 
of inhibiting or knocking down expression of one isozyme. Additionally, transient 
transfection to over-express an isozyme creates an artificial system and assumptions 
must be made as to whether other pathways are affected that could influence acetylation 
levels. Furthermore, these methods typically monitor protein acetylation levels by 
immunoblotting, so substrate discovery is both limited and biased due to the protein of 
interest needing to be predetermined.  
Acetylation sites on histone tails have been described as in vivo substrates for all 
Class I HDACs. Histones have been further validated as substrates through in vitro 
deacetylation assays with both peptide analogs and full-length protein. Site selectivity has 
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additionally been explored for histones using both hyperacetylated full-length histones, 
where acetylation level was detected with site-specific antibodies, and singly acetylated 
synthetic peptide analogs[86-88]. HDACs 1, 2 and 3 catalyze deacetylation of all the 
analyzed acetylated lysines in histone tails but with varying efficiency[86-88] (Figure 1.6). 
It should be noted the activity for HDAC1, 2, and 3 are for their immunopurified, 
complexed states whereas the activity for HDAC8 is from E. coli recombinant enzyme. 
The different complex components surely infer selectivity, but the substrate selectivity of 
each complex is unknown.  
 
Figure 1.6: Relative activity of Class I HDACs on various histone acetylation sites 
Class I HDACs have been linked to several other nuclear non-histone substrates. 
The transcription factor, p53, was one of the first proposed non-histone protein 
substrates. Deacetylation of p53 has been linked to multiple isozymes through non-
selective in cellulo inhibition and transient transfection, as well as in vitro peptide 
analogs[46, 47, 89]. The following protein substrates have only been proposed through 
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cellular experiments and lack in vitro evidence. Both HDAC1 and HDAC2 are proposed 
to catalyze deacetylation of the CCR4-associated factor 1 (CAF1) that regulates mRNA 
decay[90]. HDAC1 is additionally proposed to deacetylate DNA methyltransferase 1 
(DNMT1) preventing degradation of this protein [52]. HDAC2 is proposed to deacetylate 
TP53-binding protein 1 (53BP1). Deacetylated 53BP1 binds to damaged chromatin to 
induce DNA double-strand break repair. HDAC2 has also been proposed to deacetylate 
phosphatase PTEN down-regulating activity and recruitment to signaling complexes. 
Lastly, HDAC3 is proposed to deacetylate p65 leading to the nuclear export of the nuclear 
factor kappa B (NF-B) transcription factor complex, repressing transcription[91]. 
HDAC8-specific protein substrates have been validated both in vivo and in vitro. 
The best validated HDAC8 substrate is acetylated structural maintenance of 
chromosomes protein 3 (SMC3), identified through loss of function mutations in the 
HDAC8 gene that occur in some patients with the developmental disorder, Cornelia de 
Lange syndrome[50]. Acetylated SMC3 has been further validated by HDAC8-specific in 
cellulo inhibition and in vitro deacetylation by HDAC8[50]. Estrogen related receptor-alpha 
(ERR) deacetylation is also proposed to be catalyzed by HDAC8, increasing ERR’s 
DNA binding affinity[92]. Acetylated ERR has been validated by in vitro co-
immunoprecipitation with HDAC8 and in vitro deacetylation by HDAC8[92].  
HDAC6 has been linked to numerous cytosolic substrates. The most extensively 
validated proposed protein substrates are heat shock protein 90 (HSP90) and tubulin. 
HDAC6 has been shown to associate with HSP90 and tubulin/microtubules in vivo[58, 
61]. Inhibition of HDAC6, in addition to over-expression has also been shown to affect the 
acetylation of HSP90 and -tubulin in vivo[58, 61]. The effect of deacetylation is opposite 
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for the two substrates as deacetylation enhances HSP90 chaperone activity[61] and 
deacetylation of tubulin increases microtubule instability[58]. HDAC6 catalytic activity 
towards HSP90 and -tubulin, when assembled in microtubules, has also been validated 
in vitro[58, 61]. HDAC6 has additionally been proposed to deacetylate other protein 
substrates, however they have not been validated in vitro. HDAC6 is proposed to catalyze 
the deacetylation of cortactin, promoting binding of cortactin to F-actin, enhancing cell 
motility[57], and the protein tau, promoting microtubule binding and preventing 
pathological aggregation[93-95]. HDAC6 has also been linked to nuclear substrates. 
HDAC6 is proposed to deacetylate RNA binding protein TDP43 preventing the 
aggregation of the hyperphosphorylated form of TDP43[62].  The aggregated form of 
TDP43 is implicated in the development of amyotrophic lateral sclerosis (ALS).  
Lastly, HDAC11 associates with and is proposed to deacetylate the replication 
licensing factor, Cdt1, protecting this protein from proteasomal degradation[96]. HDAC11 
additionally associates with and is proposed to deacetylate forkhead box P3 (Foxp3) in 
T-regulatory cells[43]. Both protein substrates are proposed solely by in vivo transient 
transfection and over-expression of HDAC11[43, 96].  
The substrates summarized here likely represent a small number of thousands of 
potential substrates, as measured by the existence of acetylated proteins in cells. It is 
apparent traditional experiments are inefficient at identifying the potential multitude of 
substrates these enzymes act on. Promising high-throughput ways of identifying 
substrates have been developed in recent years.  
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The HDAC Activity “Toolbox” 
 
Figure 1.7: New substrate discovery methods.  
A) Scheme of in cellulo inhibition. B) Scheme of active site photo-crosslinking. C) Scheme of substrate 
trapping. D) Scheme of active site computational modeling.  
 
One method that has been utilized to determine HDAC-specific substrates is in 
cellulo inhibition. In 2014, Olson et al. used the HDAC8-specific inhibitor, PCI-34051, to 
increase acetylation of HDAC8 substrates in cell culture[97]. The proteins with 
substantially increased acetylation due to HDAC8 inhibition were identified using SILAC 
(stable isotopic labeling of amino acids in cell culture) mass spectrometry (Figure 1.7-A). 
This study was not without its limitations. Only seven proteins were identified as high-
confidence HDAC8 substrates. The lack of substrates identified could be due to the 
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redundant activity of HDACs; once HDAC8 was inhibited another HDAC was able to fill 
in. The lack of identified substrates could also be due to the low cellular viability of the 
hydroxamate inhibitor. The experiment was run over 24 hours, much longer than the 1-
hour lifespan of hydroxamates in the cell. By the end of the 24 hours a portion of HDAC8 
activity would have been restored. Furthermore, this experiment does not demonstrate 
HDAC8 directly catalyzes deacetylation of these substrates; alteration of the activity of 
another protein by the inhibitor could lead to decreased acetylation. 
The limitations seen with inhibitor use to identify substrates have promoted 
development of substrate-trapping methods. Two methods that have been developed are 
active site photo-crosslinking (Figure 1.7-B) and inactive trapping mutants (Figure 1.7-
C). Active site photo-crosslinking has been used to identify over 100 potential HDAC8 
substrates[98]. This method incorporates a non-canonical amino acid at an amber stop 
codon to genetically encode a photo-crosslinker, in this case p-benzoyl-L-phenylalanine, 
proximal to the active site of HDAC8. Transient substrate-enzyme interactions are 
covalently captured by the photo-crosslinker upon activation with light. In this experiment 
human tissue culture cell lysates were incubated with recombinant labelled-HDAC8 and 
potential substrates captured by covalent crosslinking. The identity of the captured 
proteins was determined by bottom-up mass spectrometry with high stringency controls. 
The method is high-throughput and effective, identifying the largest number of potential 
substrates. However, the use of cell lysates and recombinant protein is a limitation due 
to the loss of cellular compartmentalization and possible disruption of protein complexes.  
 In contrast, inactive substrate trapping mutants are expressed in vivo. The mutants 
are optimized to display no activity but high substrate binding allowing the isolation of the 
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enzyme-substrate complex. The method has been successfully used with HDAC1 to 
identify LSD1 as a novel substrate[99] and identified p53 as a control substrate[100]. The 
two substrates were identified using two different mutants, indicating screens of multiple 
mutants must be performed to ensure widespread coverage of substrate interactions. 
Furthermore, the mutations may alter substrate selectivity and/or complex formation. 
When this method was coupled to a proteomic, mass spectrometry analysis only six high-
stringency hits were found[101].   
 A last method to help identify substrates is computational modeling. Alam et al. 
developed a structure-based approach to identifying substrates of HDAC8 (Figure 1.7-
D) [102]. Based on the Rosetta FlexPepBind framework, the computational model 
predicts “good” substrates. The model fits peptide analogs of acetylation sites into the 
active site of HDAC8, determined by crystallography, and calculates if the fit is good 
enough for efficient binding and catalysis. The HDAC8 model demonstrated a linear 
correlation between the predicted binding and the log kcat/KM for catalysis of peptide 
deacetylation and predicted the fastest HDAC8 peptide substrate described thus far. This 
method is more comprehensive than the others discussed. Due to the computational 
nature of the screen all the acetylation sites identified in the proteome can be rapidly 
screened as a potential HDAC8 substrate. However, this model format assumes 
substrate selectivity can be predicted at the peptide level.  
 In addition to discovering substrates, the deacetylase activity with the proposed 
substrates must be determined. The kinetic parameter, kcat/KM, evaluated for each 
substrate gives insight into substrate selectivity. Deacetylase activity assays have been 
developed for peptide analogs of substrates and for full-length protein substrates. The 
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commercially available Fluorr de Lys assay measures deacetylase activity with peptide 
analogs[103]. The peptides contain an acetylated lysine reside within a 5-mer peptide 
and a C-terminal methyl-coumarin fluorescent tag. Upon deacetylation, the coumarin tag 
is released by reaction with trypsin which leads to a change in fluorescence (Figure 1.8-
A). The fluorescent tag dramatically increases ease of use and sensitivity of deacetylation 
activity. However, it is cost prohibitive to fluorescently tag all peptides one may want to 
test, outside of those commercially available. The methyl-coumarin tag interacts with 
HDACs and enhances the catalytic activity, so results may not be directly applicable to 
selectivity of in vivo substrates.  
 
Figure 1.8: HDAC activity assays 
(A) Commercially available Fluor de Lys assay. (B) Enzyme-coupled acetate assay. (C) Peptide mass 
spectroscopy assay. (D) Immunoblotting assay. 
 
  An enzyme coupled assay measuring acetate production developed by Wolfson 
et al. allows determination of deacetylase activity on non-labeled peptides[104]. The 
assay couples the production of acetate to NADH formation, harnessing enzymes from 
the citric acid cycle, which can be monitored via fluorescence[104] (Figure 1.8-B). The 
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enzyme coupled assay broadens the scope of peptide substrates to be tested and has 
been used to validate potential substrates identified from some of the previous methods.  
The enzyme coupled assay is still limited by its use of peptide analogs of 
substrates. Castaneda et al. demonstrated that HDAC8 catalytic efficiency increases 
when full-length acetylated H3/H4 is used versus the peptide analog, thus biologically 
relevant rates must be determined using full-length substrates[88]. Castaneda et al. used 
genetically encoded non-canonical amino acid incorporation to express singly acetylated 
histones. The catalytic rate was then determined through mass spectrometry of the 
peptide fragments of the histones after they had been subjected to deacetylation by 
HDAC8 (Figure 1.8-C). Deacetylation of acetylated full-length proteins has also been 
measured by anti-acetyl-lysine immunoblotting (Figure 1.8-D). The catalytic rate is 
determined by the disappearance of acetylated protein over time. This immunoblotting 
method has been demonstrated using both HDAC8 and HDAC1[105, 106]. 
Discovery of HDAC-specific substrates using these methods has greatly evolved 
our understanding of the biological function of these enzymes. HDAC’s biological function 
cannot be fully determined by just substrates, however, as there are many other factors 
that regulate function and selectivity.  
Identity of Active Site Metal 
 As mentioned, HDACs are metal-dependent deacetylases. It is thought the active 
site metal ion is zinc(II), based on the first crystal structure of HDAC8 showing a zinc ion 
in the active site[107]. However, the His-Asp-Asp metal binding site is uncharacteristic for 
a zinc binding site[108] raising the possibility another metal might be more suited. The 
effect of different divalent metals in the active site has been extensively studied using 
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HDAC8. HDAC8 has thus become the most extensively biochemically characterized 
HDAC and serves as a model for the HDAC catalytic mechanism.  
Crystal structures have been solved with multiple divalent metals, including Co(II), 
Zn(II), Fe(II), and Mn(II)[109]. No significant structural differences in a hydroxamate-
bound active site are apparent. However, the deacetylase activity is dependent on the 
identity of the reconstituted metal as follows:  Co(II)>Fe(II)>Zn(II) and minimal activity is 
observed with Ni(II) and Mn(II)[110]. Due to the intercellular availability of the divalent 
metals, it is proposed the in vivo active site ion is Zn(II) or Fe(II). The KD values of HDAC8 
for Zn(II) and Fe(II) are significantly different, 5pM and 2M respectively[111]. However, 
the free Zn(II) cellular concentration is estimated in the picomolar range[112, 113] and 
coincidingly the available Fe(II) concentration is within the micromolar range[114, 115]. 
Considering the KD values are comparable to cellular concentrations of the two metals, it 
cannot be determined based on the affinities and concentrations of Zn(II) and Fe(II) which 
is the in vivo active site metal. 
 It is possible HDAC8 exists as both a Zn(II) and Fe(II) deacetylase. When 
expressed in E.coli, recombinant HDAC8 contains more iron than zinc[110]. Furthermore, 
the activity in E.coli cell lysates is oxygen-sensitive[110], indicating the presence of 
oxygen-sensitive Fe(II). It has previously been shown a bacterial deacetylase, UDP-3-O-
((R)-3-Hydroxylmyristoyl)-N-acetylglucosamine Deacetylase (LpxC), initially labeled as a 
zinc-dependent deacetylase, is an iron-dependent deacetylase and undergoes a 
regulatory metal-switching mechanism[116, 117].  The similarities between the two 
deacetylases, LpxC like HDAC8, is more active with an iron cofactor than zinc, could 
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indicate HDAC8 additionally has a metal-switching regulatory mechanism. However, 
there is currently little information about the identity of the metal bound to HDAC8 in cells.  
 In addition to increased activity with Fe(II), the peptide selectivity of HDAC8 is 
dependent on the identity of the reconstituted metal. Castaneda et al. demonstrated that 
HDAC8 activity with acetylated peptide substrates varies between 2-150 fold when the 
reconstituted metal switched from Zn(II) to Fe(II)[118]. Additionally, the most substantial 
differences were seen with peptide analogs of potential substrates identified through a 
proteomic screen. Such a finding suggests that HDAC8-Fe(II) may be an important in vivo 
species and increases the probability that a metal-switching mechanism is involved in 
biological HDAC8 function.  
The exploration of different active site metals with HDAC8 has elucidated a 
potential important regulatory mechanism of HDACs. It is clear the identity of the divalent 
metal in HDACs is important for activity and selectivity.  
Post-translational Modifications 
 As with many proteins, HDAC’s are regulated by post-translational modifications. 
HDACs can be acetylated, glycosylated, ubiquinated, sumoylated, and 
phosphorylated[6]. The most extensively studied modification is phosphorylation as 
almost every HDAC is phosphorylated, but the PTM occurs at different sites with different 
effects.  
HDAC1 is doubly phosphorylated at Ser421 and Ser423. HDAC2 is 
phosphorylated at the corresponding residues, Ser422 and Ser424. The phosphorylation 
of HDAC1 and HDAC2 seems to be essential for catalytic activity. Pflum et al. found that 
HDAC1 mutants with the phosphorylated serine changed to alanine reduced deacetylase 
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activity by 80% and the corresponding phosphomimetic mutants (glutamate) rescued 
activity[119]. The results could not differentiate whether both phosphorylation sites were 
necessary for activity, but mass spectrometry analysis of immunoprecipitated HDAC1 
demonstrated phosphorylation of both sites[119]. The study additionally found that 
phosphorylation was important for complex formation. The mutant HDAC1 that removed 
the phosphorylation sites did not co-immunoprecipitate with known complex 
partners[119]. It should be noted that the effect of phosphorylation on activity has only 
been observed with full-length protein substrates, e.g. histones. There is no appreciable 
difference between  the activity of phosphorylated and non-phosphorylated HDAC1 with 
peptide substrates[120]. This indicates that the changes caused by phosphorylation likely 
do not directly affect the activity of the metal site. However, it is unknown if such an effect 
is caused by the lack of interacting proteins with non-phosphorylated HDAC1. HDAC3 is 
similarly activated by phosphorylation. HDAC3 is phosphorylated on an unconserved 
residue, Ser424. Like HDAC1 and HDAC2, the modification is critical for enzymatic 
activity[121].  
 The last Class I member, HDAC8, is also regulated by phosphorylation. HDAC8 is 
unique in the Class I enzymes, in that phosphorylation inhibits deacetylase activity. Lee 
at al. found HDAC8 is phosphorylated at Ser39, an unconserved residue within the 
catalytic domain. An unphosphorylated mutant (S39A) had no effect on activity, whereas 
a phosphomimetic mutant (S39E) significantly decreased deacetylase activity with 
purified histones[122]. Recently, Welker Leng et al. found that the magnitude of the 
activity decrease of the phosphomimetic mutant (glutamate) was dependent on peptide 
substrate sequence. Activity decreases varied between 10 and 100-fold dependent on 
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the peptide substrate[123]. The study demonstrates a potential role of phosphorylation in 
not only regulating activity but also regulating selectivity of HDACs.  
 Phosphorylation of Class IIa HDACs affects the cellular localization and in doing 
so, their regulation of transcription. All members of Class IIa (HDAC4, HDAC5, HDAC7, 
and HDAC9) are phosphorylated at three, conserved serine residues. Phosphorylation at 
all three residues induces binding of 14-3-3 proteins, preventing the identification of the 
nuclear localization signal[30, 32]. The HDACs are then transported out of the nucleus 
into the cytoplasm. This change in cellular localization prevents Class IIa HDACs from 
interacting with myocyte enhancing factor-2 proteins (Mef2)[31, 81, 124]. Mef2 proteins 
are then free to activate gene transcription. In that respect, phosphorylation of Class IIa 
HDACs inhibits their transcriptional repression activity.  
 HDAC6 has the most complex regulation by phosphorylation. HDAC6 does not 
require phosphorylation to be active but HDAC6 is found in vivo to be phosphorylated at 
multiple sites, and the change in activity is dependent on the site. Deribe et al. found 
phosphorylation by epidermal growth factor receptor kinase (EGFR) at Tyr570 abolishes 
deacetylase activity as measured by increased acetylation of -tubulin in vivo[125]. In 
contrast, Williams et al. found extracellular signal-regulated kinase 2 (ERK2) 
phosphorylates Ser1035 of HDAC6 through the EGFR-Ras-Raf-MEK-ERK signaling 
cascade, stimulating cell migration[126]. Ser1035 phosphorylation enhances in vitro 
deacetylase activity with -tubulin as a substrate but does not affect in vitro deacetylase 
activity towards core histones[126]. Additional studies further demonstrate regulation of 
HDAC6 activity by phosphorylation. Ser458 and Ser22 are also phosphorylation sites that 
stimulate HDAC6 deacetylase activity. Prevention of phosphorylation at Ser22 decreased 
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HDAC6 catalytic activity when measured in cell lysates using a peptide fluorometric 
assay[127]. Phosphorylation at Ser458 increased recombinant HDAC6 catalytic activity 
when measured in vitro using a peptide fluorometric assay. [127, 128]. HDAC6 
phosphorylation has also been linked to viral sensing, where phosphorylation by protein 
kinase c-alpha (PKC) enhances -catenin deacetylation leading to interferon 
transcription[129]. Regulation of HDAC6 by phosphorylation demonstrates how 
deacetylase activity is crucial to biological signaling pathways.  
 HDAC10 and HDAC11, the least studied HDACs, have no confirmed, regulatory 
PTM sites. PhosphoSitePlus lists several PTMs found for both enzymes, however they 
have only been identified through high-throughput proteomic screens[6]. Based on the 
rest of the HDAC family, HDAC10 and HDAC11 are most likely regulated by 
phosphorylation or other PTMs but further research is needed to determine the effect.  
 Modifications of HDACs, particularly phosphorylation, greatly impact the enzyme 
activity. HDAC8, and potentially HDAC6, serve as models that phosphorylation changes 
both activity and substrate selectivity. Involvement in specific biological pathways could 
be dependent upon phosphorylation and the site of phosphorylation.  
Conclusion 
This dissertation seeks to further explore the factors that affect the activity and 
selectivity of histone deacetylases. The work focuses on three HDACs: HDAC1, HDAC6, 
and HDAC8. In Chapter 2, HDAC8 will be used as a model to attempt to elucidate the in 
vivo active site metal by metalloform-specific inhibition with the identification of several 
metal-binding groups selective for HDAC8-Fe(II) versus HDAC8-Zn(II). Novel non-
hydroxamate metal chelator fragments were also analyzed with HDAC8 for inhibitor 
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development with the tropolone metal binding group identified as the most potent lead 
molecule for future studies.  
In Chapter 3, HDAC1 will serve as a model for elucidating how complexation and 
protein interactions affect substrate selectivity. This was accomplished by reconstituting 
the HDAC1-containing CoREST complex in vitro and determining activity across multiple 
potential substrates. These data demonstrated that protein interactions enhance HDAC1 
deacetylase activity significantly and activity enhancement can be achieved regardless of 
the expression system.  
Finally, in Chapter 4, the computational substrate discovery method will be tested 
on HDAC6, to determine if the substrate selectivity for Class IIb HDACs can be 
determined at the peptide level. A computational model to predict good substrates of the 
second catalytic domain of HDAC6 was successfully created, though this domain 
demonstrated low substrate sequence selectivity overall. The addition of the first catalytic 
domain changed selectivity and activity, indicating that the full structure is important for 
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Chapter 2 : Novel Non-Hydroxamate Inhibition of Histone Deacetylases* 
 
Introduction 
Histone deacetylases have been attractive cancer drug targets due to their 
involvement in the regulation of gene transcription[1-7] and overexpression of HDACs 
has been implicated in numerous cancers[8]. There are currently four FDA-approved 
inhibitors of Class I HDACs for use in treatment of T-cell lymphoma and multiple 
myeloma[8]. Developed HDAC inhibitors have a consistent structure: zinc binding group 
(ZBG) – linker – cap. The linker and cap groups form contacts within the substrate binding 
tunnel and protein surface, respectively, and can be varied to confer isozyme selectivity. 
The ZBG is the primary mode of inhibition as it binds to the divalent active site metal 
displacing the water nucleophile necessary for catalysis. Hydroxamates have been 
commonly used as ZBGs, present in 3 of the 4 FDA approved inhibitors, as the group is 
a potent metal binder. However, hydroxamates have poor pharmacokinetics with an in 
vivo half-life of less than an hour due to the susceptibility of the hydroxamate to hydrolysis 
under physiological conditions[9]. It can additionally be difficult to achieve good selectivity 
due to the Zn(II) binding contributing a large portion of target affinity[9]. The issue of 
selectivity extends to all Zn(II) enzymes and within the HDAC family; all the FDA approved 
inhibitors are non-selective pan-HDAC inhibitors and exhibit high toxicity  
*Previous students George Murphy III and Hannah Foley also contributed to this work. George Murphy III 
performed the initial screen of CFL1 with HDAC8-Zn(II) and HDAC8-Fe(II). Hannah Foley assisted in 




due to the large effect HDACs 1-3 in particular have on gene regulation[8]. Yet other 
common ZBGs, benzamides, carboxylic acids etc., have been unable to match the 
potency of the hydroxamate[10].  
Research is currently ongoing to develop novel, non-hydroxamate metal binding 
groups for HDAC inhibitors[8, 11-14]. The focus has been on developing inhibitors with 
binding groups specific to Zn(II), due to it being widely accepted that HDACs are Zn(II)- 
deacetylases. The initial HDAC8 crystal structure showed Zn(II) present in the active site 
following reconstitution[15]. However, the Asp-Asp-His metal binding site is 
uncharacteristic of a zinc binding site[16] leading to the HDAC8 active site being 
extensively studied biochemically and structurally. HDAC8 binds and is activated by 
additional metal ions, including Fe(II) and Co(II)[16, 17] and it has been shown that the 
catalytic efficiency and inhibitor affinity varies dependent on reconstituted metal[17]. Yet 
crystal structures of reconstituted HDAC8 with various metals do not illustrate any 
structural differences that would account for the different activity[16]. It should be noted 
that all these crystal structures contain a hydroxamic acid inhibitor suggesting the 
possibility that the inhibitor alters the geometry of the bound metal ion. 
HDAC8 activity in cells has additionally demonstrated oxygen sensitivity 
suggesting the potential importance of Fe(II) in cellular HDAC8 activity[17, 18]. 
Alternatively, the oxygen sensitivity of HDACs has been proposed to be due to redox 
sensitivity. Most Class I HDACs (HDAC1, HDAC2, and HDAC3) have two conserved 
cysteine residues which can be alkylated by reactive carbonyl species (RCS), a 
downstream product of reactive oxygen species (ROS), causing decreased deacetylase 
activity[19]. Class II HDAC4 additionally has been found to contain a cysteine pair 
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sensitive to oxidation in response to ROS[20]. HDAC8 has been the most recent HDAC 
reported to have a redox switch[21], where the oxidized form is inactive. The presence of 
an inactivating redox switch could explain HDAC8 oxygen sensitivity in cell lysates.  
Nonetheless additional studies have also demonstrated that the substrate selectivity 
varies with the metal ion bound to HDAC8[22] implicating the identity of the active site 
metal as a potential regulatory mechanism. The identity of the active site metal in 
endogenous HDAC8 has been yet to be determined with certainty.  
This chapter details the discovery of novel non-hydroxamate inhibitors by use of a 
metal-chelating fragment library. Some fragments displayed selectivity for inhibition of 
Fe(II)-compared to Zn(II)-bound HDAC8, leading to these fragments being further 
structurally modified. These elaborated inhibitors were then used to probe the active site 
metal bound to HDAC8 in cells but no evidence indicating the presence of HDAC8-Fe(II) 
was obtained.   
Materials and Methods 
Reagents 
Trace metal certified HEPES, sodium chloride, and potassium chloride were 
purchased from Sigma. Trace metal certified tips were purchased from Corning (4869, 
4694). All other materials were purchased from Fisher at >95% purity unless noted 
otherwise. 
CFL1 Library and Expanded Inhibitors 
Prof. Seth Cohen at the University of California San Diego graciously provided the 
96-member metal chelator fragment library, CFL1[23], as 50 mM stock solutions in 
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dimethyl sulfoxide, DMSO. The expanded inhibitors were additionally synthesized in the 
Cohen lab and provided as 50 mM stock solutions in DMSO.  
Purification of apo-HDAC8 
Apo-HDAC8 was expressed and purified, followed by reconstitution with Zn(II), 
Fe(II), or Co(II) as previously described[17] with the following modifications. HDAC8 was 
reconstituted at a 1:1 molar ratio with Zn(II) using a 1000 ppm Zn ICP standard by 
incubation on ice for 1 hour. HDAC8 was reconstituted with Co(II) at a 2:1 molar ratio 
using a 1000 ppm Co ICP standard by incubation on ice for 1 hour. For reconstitution with 
Fe(II), HDAC8 in storage buffer (25mM MOPS, 1mM TCEP, 5mM KCl) was equilibrated 
in a Coy labs anaerobic chamber on ice for 1 hour before reconstitution at a 5:1 molar 
ratio using a solution of Fe(II) sulfate heptahydrate with excess ascorbic acid (50-fold) in 
reaction buffer (25 mM HEPES pH 7.5, 137 mM NaCl, 2.7 mM KCl) on ice for 1 hour. For 
activity assays, the HDAC8-Fe(II) was removed from the anaerobic chamber and assayed 
within 1-2 hours with minimal loss in activity.  
The concentration of HDAC8 was determined by titration with fluorescein-SAHA 
(previously synthesized[24]). Increasing amounts of HDAC8-Co(II) were added to 100 nM 
fluorescein-SAHA (SAHA Ki=44nM) in individual wells of a Corning 3686 96-well half area 
microplate (previously soaked in 0.5 mM EDTA, thoroughly rinsed with water and dried). 
The change in fluorescent polarization (ex. 485 nm, em. 535 nm) was determined after 
incubation at room temperature for 15 minutes. The data was analyzed using GraphPad 
Prism to determine the stoichiometric point of saturation and the adjusted concentration 
of HDAC8.  
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Metal-Chelating Fragment Library Screen 
HDAC8 activity in the presence of the metal-chelating fragments was determined 
by the Fluor de Lys assay using Enzo Life Sciences Fluor de Lys HDAC8 substrate and 
Developer II solutions. A control reaction was performed using 0.5 M HDAC8, 50 M 
HDAC8 substrate in 10% DMSO, and reaction buffer. The 50 mM inhibitor stocks in 
DMSO were diluted to 2 mM in DMSO. The inhibitor, at a final concentration of 200 M, 
was added to 50 M HDAC8 substrate in 1X buffer, preheated to 30°C, and the reaction 
was initiated with 0.5 M HDAC8. Various aliquoted timepoints (5 L) were diluted into 
45 L quench solution (0.73% Developer II, 1.2M trichostatin A, 1X buffer) in individual 
wells of a Corning 3694 96-well half area microplate. After a 10-minute room temperature 
incubation, the fluorescence of the remaining substrate (ex. 360 nm, em. 362 nm) and 
resulting product (ex. 360 nm and em. 460 nm) was determined using a PolarStar plate 
reader. The amount of product in each inhibitor reaction was compared to the control 
reaction to obtain the % retained activity. 
Dose Response Curves 
HDAC8 activity was determined using the Fluor de Lys assay. A control reaction 
was performed containing 0.5 M HDAC8, 50 M HDAC8 substrate in 10% DMSO, 1X 
buffer. The 50 mM inhibitor stocks in DMSO were diluted to various concentrations such 
that each assay contained a final concentration of 10% DMSO. The diluted inhibitor was 
added to 50 M HDAC8 substrate in 1X buffer, preheated to 30°C, and the reaction was 
initiated by addition of 0.5 M HDAC8. Various timepoints (n=4) were quenched in 
individual wells of a Corning 3694 96-well half area microplate and fluorescence 
determined as previously described. The initial rate of each reaction was compared to the 
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control reaction to obtain the remaining activity (%). The IC50 value was obtained from a 
fit of Equation 2.1 to the dependence of the activity on the inhibitor concentration (x) 










Reconstituted HDAC8-Fe(II) (9M) was incubated with inhibitor (at 3 times IC50) or 
DMSO as a control at 30°C for 1 hour under anaerobic conditions in 1X buffer using a 
Coy anaerobic chamber. The samples were then removed from the anaerobic chamber 
and processed through Zeba spin 7K MWCO desalting columns (ThermoScientific) to 
remove unbound inhibitor and Fe(II). A portion of the desalted sample (15 L) was diluted 
to 500 L with water for Bradford analysis and the remaining sample (30 L) was diluted 
to 1 mL with 2% metal-free nitric acid for ICP-MS analysis. Coomassie Plus reagent 
(ThermoScientific) was used to determine the HDAC8 concentration using a Bradford 
assay. Each desalted, diluted sample was assayed in triplicate and analyzed against an 
HDAC8 standard curve following the manufacturer (ThermoScientific) protocol. An 
Agilent 7900 ICP-MS was used to determine the total Fe concentration. The Fe 
concentration of each desalted, diluted sample was determined from triplicate analysis in 
the High-Energy Helium mode against a 56 Fe standard curve with 71 Ga as an internal 
standard. The Fe concentration of the desalted sample was compared to the HDAC8 




Fe(II) was prepared from Fe(II) sulfate heptahydrate in an anaerobic chamber in 
the presence of excess ascorbic acid (50-fold). Increasing concentrations of inhibitor 
(10% DMSO in 1X buffer) were added to a constant concentration of Fe(II) in individual 
wells of a Corning 9017 96-well microplate. The absorbance of each well was measured 
at the max of the inhibitor-Fe(II) complex using a SpectraMax plate reader. A binding 
equation (Equation 2.2) was fit to these data using GraphPad Prism to determine the KD 
for the inhibitor- Fe complex with variable hill slope (h) and ymax = max absorbance 
change. 






Oxygen Sensitivity of HeLa cell lysates 
HeLa cells were purchased from ATCC (CCL-2) and were grown in Gibco™ 
Dulbecco’s modified eagle medium, high glucose (ThermoScientific) supplemented with 
10% Hyclone fetal bovine serum in T75 flasks until 80-90% confluent. Cells were 
harvested using Gibco™ 0.25% Trypsin-EDTA (ThermoScientific), where the sample was 
stained with trypan blue and the cells counted with a hemocytometer. 1 million cells were 
lysed in 1X buffer containing 1% Tween-20 and Halt Protease/Phosphatase Inhibitor 
Cocktail (ThermoScientific) by incubation on ice for 30 minutes under anaerobic 
conditions. Following lysis, half of the sample was removed from the anaerobic chamber 
and exposed to oxygen on ice for at least 3 hours. The rest of the sample remained under 
anaerobic conditions on ice for the same amount of time. The HDAC activity of the aerobic 
and anaerobic lysate was determined using the Fluor de Lys assay with 100 M HDAC8 
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substrate at 30°C. For each sample, initial and final reaction time points were collected 
(run in triplicate). Using GraphPad Prism, the reaction rate was determined from the linear 
correlation between the initial and final timepoints. The different sample means were 
compared by 2-way ANOVA with Sidak multiple comparisons correction[25].  
Results  
Select fragments display potent inhibition 
The initial screen of the chelator fragment library, CFL1, revealed multiple 
fragments that were efficient at inhibiting activity of both HDAC8-Zn(II) and HDAC8-Fe(II) 
(Figure 2.1-A). Of the 96 fragments screened, 10 displayed greater than or equal to 50% 
inhibition at 200 M (Table 2.1). The fragments that displayed the best inhibition against 
HDAC8-Zn(II) and HDAC8-Fe(II) were further tested against HDAC8-Co(II) where they 
additionally displayed good inhibition (Figure 2.1-B). To further characterize inhibition, 
the IC50 values of select compounds was determined and the IC50 values of three of these 
compounds are below 30 M (Figure 2.2). One of those fragments, G12, has an IC50 





Figure 2.1: Heat maps illustrating inhibitor potency. 
Grayscale is given for remaining HDAC8 activity (%), more black indicates higher % activity, more white 
indicates less % activity. A) All CFL1 fragments against HDAC8-Zn(II) and HDAC8-Fe(II). B) Selected 





Table 2.1: CFL1 Library Fragments screened against all HDAC8-reconstituted forms 
 
 HDAC8-Zn(II) HDAC8-Fe(II) HDAC8-Co(II) 






B2  10 31 66 
B7  40 0 10 
D6  21 36 27 
D8  33 0 14 
E1  20 0 6 
E2  0 7 10 
G8  57 0 n.d. 
G11  26 18 5 
G12  16 3 0 
H1  0 6 10 
aRetained activity determined from comparison of reconstituted HDAC8 activity with 200M inhibitor to 10% DMSO 




Table 2.2: IC50 values of most potent inhibitor fragments 
 




 (M) Hill Slope IC
50
 (M) Hill Slope IC
50
 (M) Hill Slope 
D8 90 ± 30 -1.3 ± 0.7 26 ± 2 -1.07 ± 0.06 40 ± 20 -1.2 ± 0.4 
H1 8 ± 2 -1.5 ± 0.7 n.d.b n/a 20 ± 10 -0.8 ± 0.4 
G11 19 ± 8 -0.9 ± 0.3 11.2 ± 0.4 -2.0 ± 0.4 8 ± 3 -2 ± 1 
G12 0.6 ± 0.3 -2 ± 1 0.7 ± 0.2 -2 ± 1 0.49 ± 0.03 -2.0 ± 0.1 
aThe IC50 value (mean ± standard error) was determined from dose response curves fit with Equation 2.1 to allow for 
variable hill slopes. Hill slopes (mean ± standard error) were determined from GraphPad Prism analysis using 













































Figure 2.2: Dose response curves of most potent inhibitor fragments against 0.5M HDAC8-Co(II). 
Each point is the initial velocity calculated from a linear fit of stopped timepoints (n=4). Error bars indicate 
the standard error.  
 
HDAC8-Fe(II) selective inhibition 
Interestingly, a greater number of fragments, 27 out of 96, inhibited HDAC8-Fe(II) 
significantly more than HDAC8-Zn(II), 10 out of 96. No fragments were found that inhibit 
HDAC8-Zn(II) more than HDAC8-Fe(II). The IC50 values for two fragments, D4 and D5, 
were at least 20 times lower for HDAC8-Fe(II) compared to HDAC8-Zn(II) (Figure 2.3). 
To develop even better HDAC8-Fe(II) specific inhibitors, a small library of compounds 
were prepared by Dr. Christian Perez from the Cohen group where the structure of these 
two fragments was elaborated by attaching various linker lengths and cap groups onto 
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the metal-chelating group (Figure 2.4). In general, these added structural features had 
modest effects on the IC50 values and on the selectivity for inhibition of HDAC8-Fe(II) 
(Figure 2.5, Table 2.3). However, more variability in the selectivity for HDAC8-Fe(II) 
compared to HDAC8-Zn(II) was observed for the D5 based compounds, HPT (Table 2.3). 
The expanded compounds for D4, named HPO, showed some improved inhibition with 
two compounds having IC50 values below 10 M, HPO6 and HPO12, for inhibition of 
HDAC8-Fe(II) (Table 2.3).  HPO12 also enhanced inhibition of HDAC8-Fe(II) by 5-fold 
compared to the parent compound (D4).  
 
Figure 2.3: Metalloform selective inhibitors dose response curves. 
The curves illustrate the higher effectiveness against HDAC8-Fe(II) versus HDAC8-Zn(II). Each point is 






Figure 2.4: Modification of 4D (left) and 5D (right). 
The HPO series is shown in blue. The HPT series is shown in green. Naming for both includes the 





Figure 2.5: Dose response curves of selected expanded inhibitors. 
A) Dose response curves of HPO15 with HDAC8-Zn(II) (open squares) and HDAC8-Fe(II) (filled 
squares). B) Dose Response curves of HPT6 with HDAC8-Zn(II) (open squares) and HDAC8-Fe(II) 
(filled squares). The curves illustrate that each inhibitor maintained the metal selectivity seen for the 
parent fragment. Each point is the initial velocity calculated from a linear fit of stopped timepoints (n=4). 







Table 2.3: IC50 values of parent fragments and select expanded inhibitors 
 
  
HDAC8-Zn(II)a HDAC8-Fe(II)a Zn/Fe ratiob 
IC50 (M) Hill Slope IC50 (M) Hill Slope 
 
D4 600 ± 100 -0.8 ± 0.1 18 ± 6 -0.8 ± 0.2 30 ± 10 
HPO2 240 ± 50 -0.8 ± 0.1 11.1 ± 0.8 -1.16 ± 0.08 22 ± 4 
HPO6 230 ± 60 -0.45 ± 0.06 9 ± 2 -0.7 ± 0.1 25 ± 9 
HPO12 >5,000c -0.23 ± 0.08 4 ± 2 -0.6 ± 0.2 >1250 
HPO15 320 ± 70 -1.1 ± 0.2 14 ± 2 -1.1 ± 0.2 23 ± 6 
 
D5 500 ± 100 -0.8 ± 0.2 21 ± 3 -1.1 ± 0.2 24 ± 6 
HPT2 390 ± 60 -1.3 ± 0.2 22 ± 5 -0.9 ± 0.2 17 ± 5 
HPT5 260 ± 20 -1.5 ± 0.2 66 ± 9 -1.3 ± 0.2 4 ± 1 
HPT6 610 ± 90 -1.0 ± 0.2 22 ± 2 -0.91 ± 0.07 27 ± 5 
HPT8 360 ± 40 -1.4 ± 0.2 40 ± 10 -0.6 ± 0.1 9 ± 2 
HPT12 500 ± 200 -1.1 ± 0.5 12 ± 5 -0.8 ± 0.2 40 ± 20 
HPT15 300 ± 100 -0.8 ± 0.2 30 ± 3 -0.90 ± 0.07 10 ± 3 
HPT16 800 ± 200 -0.8 ± 0.2 21 ± 4 -0.65 ± 0.08 40 ± 10 
aThe IC50 value (mean ± standard error) was determined from dose response curves fit with Equation 2.1 
to allow for variable hill slopes. Hill slopes (mean ± standard error) were determined from GraphPad Prism 
analysis using Equation 2.1. bThe ratio of Zn inhibition over Fe inhibition (± propagated error [26]). 
cInhibition did not reach below 50%.  
Specificity of inhibitor is related to IC50 
Previous measurements determined that the KD of Fe(II) for HDAC8 is 2 M[24], 
making this metal labile within the active site. Therefore, it is possible that the Fe-specific 
inhibitors are binding free Fe(II) in solution and sequestering the metal as it dissociates 
from the enzyme to form inactive, apo-enzyme rather than binding to HDAC8-Fe(II) 
(Scheme 2.1). An ICP-MS assay was developed to test for this metal stripping ability. 
The ICP-MS was used to determine how much Fe(II) remained bound to HDAC8 after 
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incubation with the inhibitors followed by rapid separation of the protein from unbound 
metal and inhibitor using spin desalting columns. These data demonstrated that in both 
libraries of expanded compounds there were structures that inhibited HDAC8 by removing 
the metal ion and ones that bound to HDAC8 (Figure 2.6).  These data also suggest a 
lower IC50 value does not indicate the formation of a HDAC8-Fe(II)-inhibitor complex and 
the mode of inhibition is likely determined by the relative affinity of the inhibitor for free 
Fe(II) and HDAC8-Fe(II).  
 
Scheme 2.1: Types of possible inhibition by metal-specific inhibitors. 
This hypothesis was confirmed by determining the KD value of the inhibitor to free 
Fe(II) using UV-Vis spectroscopy (Figure 2.7) where the formation of an Fe(II)-inhibition 
complex results in a peak in the visible range (absorbance 400-500 nm). The ICP-MS 
determined specific inhibitor, HPO15, has a KD for free Fe(II), 89 ± 5 M (h = 2.4 ± 0.2) 
that is higher than the measured IC50 value, 14 ± 2 M, consistent with an inhibition 
mechanism of formation of a HDAC8-Fe(II)-HPO15 complex. In contrast, the ICP-MS 
determined stripping inhibitor, HPO6, has a KD value for free Fe(II), <2 M (h = 2.0 ± 0.3) 
that is lower than the determined IC50 value, 9 ± 2 M, consistent with an inhibition 
mechanism of formation of apo-HDAC8. We were unable to determine the actual Fe(II) 
KD for HPO6 as the Fe(II) absorption signal is too low to measure below 2 µM (Figure 
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2.7-B). These data confirm the ICP-MS results that HPO15 binds HDAC8-Fe(II) with 
higher affinity and HPO6 binds free Fe(II) with higher affinity.  
 
Figure 2.6: Bar graphs displaying ICP-MS data of HDAC8 and Fe concentrations 
Concentration of HDAC8 (gray) and the concentration of Fe(II) (A: blue, B: green) remaining after 
incubation with inhibitors ([I]=3 x IC50). A) HPT series of inhibitors at 1:1 concentration Fe(II) to HDAC8. 
B) HPO inhibitors at 5:1 concentration Fe(II) to HDAC8. The expanded inhibitors are listed on the x-axis 
in order of increasing IC50 value. Each bar represents the average of duplicated experiments (N=2) for 
concentration of HDAC8 by Bradford assay (n=3) and concentration of Fe(II) by ICP-MS (n=3). 
 
 
Figure 2.7: Inhibitor binding to Fe(II) as measured by UV-Vis spectroscopy, 
Data fit using Equation 2.2. Each point represents an average (n=3) with error bars displaying the 
standard deviation. A) Titration curve of increasing amounts of inhibitor against 50 M Fe(II). The 
HDAC8-Fe(II) specific inhibitor, HPO15 (blue), produces a binding curve where the measured KD value 
is larger than 50 M. The metal stripping inhibitor, HPO6 (green), produces a binding curve where the 
measured KD is lower than 50M and the point of saturation is closer to the total amount of Fe(II), 
dashed line. B) Titration curve of increasing amounts of HPO6 against 2 M Fe(II). Again, the 






Treatment of HeLa cell lysates  
After determining that HPO15 was selective for HDAC8-Fe(II), it was then used to 
treat HeLa cell lysates to try to evaluate if HDAC8-Fe(II) was present. HeLa lysates had 
been previously determined to display oxygen sensitive HDAC activity[18] and this 
sensitivity was confirmed in these separate experiments (Figure 2.8, left). If the oxygen 
sensitivity of the deacetylase activity is due to the presence of HDAC8-Fe(II) then addition 
of HPO15 is predicted to decrease the deacetylase activity of the anaerobic lysates as 
much or more than the decrease observed by exposure to oxygen.  However, incubation 
of HPO15 with cell lysates did not significantly inhibit the deacetylase activity in anaerobic 
lysates (Figure 2.8, inset). Thus, HPO15 has little effect on the deacetylase activity in 
HeLa cell lysates and therefore does not provide information about the identity of the 






Figure 2.8: Deacetylase activity of HeLa cell lysates with and without treatment with 100M HDAC8-
Fe(II) specific inhibitor HPO15. 
The untreated lysates display significantly different activity when prepared anaerobically vs aerobically 
(p<0.05, left). The anaerobic activity of the HPO15 treated lysates is not significantly different than the 
untreated lysates (inset). Each point represents an average (N=3) rate from stopped timepoints (n=2).   
 
Discussion 
The CFL1 fragment library consisted of chelating groups known to inhibit 
metalloproteins. Several of the chelating groups, including pyrimidines and carboxylic 
acids, have been used in described HDAC inhibitors, yet they were not the most potent 
inhibitors. The most effective hit fragments were tropolone fragments.  
The two tropolone fragments, G11 and G12, have very similar structures with G12 
having an isopropyl group in the -position. Due to the increased potency of G12 over 
G11, it would seem the additional contacts created by this alkyl group are important for 
binding. Ononye et al. has additionally explored tropolones as potent HDAC inhibitors 
and found various substituted -and -tropolones were selective inhibitors for HDAC2 
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and HDAC8[27]. Tropolones are developed based on a natural product scaffold and have 
multiple sites of modification to impart enhanced binding and selectivity[27]. The metal 
binding moiety is additionally much more stable than the hydroxamate counterpart[27]. 
These positive qualities, combined with the facts that tropolone compounds were the best 
hits from the fragment library and the only compounds to have sub-micromolar IC50 
values, point to tropolone compounds as promising future targets for HDAC inhibition.  
An interesting outcome of the work presented in this chapter is the identification of 
metal selective inhibitors. Furthermore, the metal selectivity of the inhibitors was 
confirmed to not be due to the sequestering the labile Fe(II) by determining the relative 
affinity to the inhibitors to Fe(II) and HDAC8-Fe(II) through UV-Vis and ICP-MS assays. 
The selectivity found amongst the inhibitors for solely HDAC8-Fe(II) indicates potential 
active site structural differences that are dependent on the metal bound with the HDAC8-
Fe(II) structure distinct from HDAC8-Zn(II) and HDAC8-Co(II). Structural differences 
between the reconstituted metalloforms have been proposed previously, as the various 
metalloforms have differing activity substrate selectivity[17, 22]. Crystallography 
structural studies have not shown any differences when HDAC8 is bound to a 
hydroxamate inhibitor, therefore illustrating the need to solve structures of HDAC8 bound 
to metal selective inhibitors to capture the metalloform structure differences recognized 
in these other studies.  
We modified the two-best metal-selective library fragments, 4D and 5D, in an 
attempt to enhance potency and selectivity.  The series of expanded inhibitors, HPO and 
HPT, were found to follow the same metal dependence as the initial fragments. For the 
HPO series, each expanded inhibitor had a lower IC50 than the parent fragment, 4D. The 
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HPT series, however, did not follow the same trend. None of the expanded fragments 
had a significantly lower IC50 than the parent fragment, 5D. Thus, the addition of a linker 
and cap group did not enhance binding of the HPT inhibitors as it did for the HPO 
inhibitors meaning that potency of the HPT series was determined by the metal binding 
group itself. This is surprising considering 4D and 5D only differ by a single atom, oxygen 
for 4D and sulfur for 5D. These data suggest that the presence of two oxygen atoms as 
donors for metal binding are more suited for chelation to HDAC8-Fe(II).  
While we were able to develop inhibitors with lower IC50 values than the parent 
fragments, there was no correlation between linker length and IC50. However, there was 
a correlation between linker length and metal stripping propensity. For both the HPO and 
HPT series, longer linker lengths corresponded to enzyme specific inhibition, whereas 
shorter linker lengths corresponded to increased metal stripping. This implies the chelator 
group has preference for binding free Fe(II), as is expected considering these groups 
were selected due to their metal chelating ability, but the presence of a linker group 
mimicking the lysine side chain enhanced the affinity for binding HDAC8-Fe(II) (Scheme 
2.2). We also saw inhibitor binding free Fe(II) exhibits positive cooperativity where h ~ 2, 
indicating a dependence of the mode of inhibition on inhibitor concentration, however as 
long as the inhibitor exhibits greater affinity for HDAC8-Fe(II) this is not an issue. This 
highlights the importance of testing for relative affinities when dealing with a labile active 




Scheme 2.2: Proposed thermodynamic boxes to illustrate differences in stripping and selective inhibitors. 
The KD for Fe(II) is given on the left side and the IC50 is given on the right side. A) Box for stripping 
inhibitor HPO6. The preference for binding free Fe(II) is given from the low KD. B) Box for selective 
inhibitor HPO15. The preference for binding HDAC8-Fe(II) is given from the lower IC50 than the KD. 
We finally attempted to use the best HDAC8-Fe(II) specific inhibitor, HPO15, to 
determine if HDAC8 is present as HDAC8-Zn(II) or HDAC8-Fe(II) in the cell. However, 
the inhibitor treatment could not determine with certainty the presence of HDAC8-Fe(II). 
Biological replicates were unable to demonstrate a consistent decrease in activity 
comparable to aerobic activity. The lack of significance could be caused by other 
interactions that could occur in the more complex environment of cell lysates. It is also 
unknown whether HPO15 is specific to HDAC8 and most likely is not based on the need 
for additional modifications for tropolones to achieve HDAC isozyme selectivity[27]. 
HPO15 may potentially even bind other metalloenzymes, proteins etc. To achieve more 
confident results, further structural refinement of HPO15 to increase isozyme specificity 
and increase inhibition efficiency would be necessary.   
The work presented in this chapter represents an additional steppingstone in the 
research of HDAC inhibition and metal identity. We have identified the tropolone metal 
binding group as a potent HDAC inhibitor and further work refining the structure to 
increase selectivity will assist in targeted therapeutic development. This work was unable 
to concretely show whether HDAC8-Fe(II) exists in a significant amount in the cell, but 
we were able to develop Fe-specific inhibitors and confirm this metal specificity was due 
to Fe(II) bound to HDAC8 by ICP-MS analysis. The development of HDAC8-Fe(II) specific 
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inhibitors indicates there are structural differences in the different metal-reconstituted 
forms of HDAC8. Additional structural studies with inhibitors containing differing metal 
ligands could help elucidate these structural differences and provide insight into the 
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Chapter 3 : The formation of the CoREST complex enhances HDAC1 deacetylase 
activity and alters selectivity 
 
Introduction 
Post-translational modifications (PTMs) of proteins were first identified 60 years 
ago[1, 2] and are widespread across the proteome[3]. PTMs can regulate a protein’s 
activity, interactions, cellular localization, and degradation. Acetylation, a reversible PTM 
on lysine residues, was first discovered on histone tails[4]. Acetylated proteins were long 
thought to be limited to the nucleus, however high-throughput methods using mass 
spectrometry have identified thousands of acetylation sites throughout the cell. Since 
lysine acetylation is reversible, this modification can act as a regulatory switch. On 
histones, acetylation and deacetylation regulates gene transcription making the enzymes 
that catalyze these reactions essential for proper cell function.  
The deacetylase family is divided into four classes based on homology to yeast 
deacetylases. Classes I, II, and IV, referred to as histone deacetylases or HDACs, are 
metal-dependent deacetylases, requiring a divalent metal ion for catalysis within a 
conserved catalytic domain. HDAC1, a Class I deacetylase, is localized to the nucleus 
functioning to regulate gene transcription[5-11], cell growth[12, 13], proliferation[14-17], 
differentiation[18, 19], and apoptosis[13, 20, 21]. Mis-regulation of acetylation has been 




There are still significant gaps in our understanding of misregulation of HDAC 
functions in biological pathways that lead to disease. Many HDACs do not function alone, 
rather they form both stable and transient interactions with other proteins. BioGRID, the 
Biological General Repository for Interaction Datasets, lists almost 3,000 total protein 
interacting partners for all 11 HDACs, with almost half of those protein interactions  
connected to HDACs 1 and 2[27]. HDAC1 is known to exist in three, stable nuclear 
complexes, the NuRD[28], Sin3[29], and CoREST[30] complexes, that are proposed to 
activate the deacetylase activity of HDAC1.  
HDAC1 in complex has demonstrated catalytic activity on all four core histones, 
with varying efficiency[31].  In contrast, when purified to homogeneity HDAC1 has little to 
no deacetylase activity[32]. The role of specific protein interactions in enhancing HDAC1 
activity has not been explored. Recent studies have focused on purifying and measuring 
the activity of intact HDAC1-containing complexes purified from eukaryotic expression 
systems[33-35]. The deacetylase activity of these complexes with both single histone and 
nucleosome substrates has been shown to vary based on acetylation site with each 
complex containing its own selectivity [34-36]. The CoREST complex, consisting of lysine 
demethylase 1 (LSD1), repressor element 1 silencing transcription factor  corepressor 1 
(CoREST), and HDAC1, has demonstrated the greatest deacetylase activity with the least 
selectivity[36]. 
Additionally, HDACs are known to be regulated by post-translational modifications, 
particularly phosphorylation[37-49]. HDAC1 is doubly phosphorylated at Ser421 and 
Ser423, and this phosphorylation increases the catalytic activity with full-length protein 
substrates, i.e. histones, as well as enhancing protein-protein interactions[40, 42]. There 
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is the potential that phosphorylation regulates both activity and selectivity of HDACs. Such 
a role has recently been shown with HDAC8 where phosphorylation inhibits deacetylase 
activity, yet the activity decreases vary between 10 and 100-fold, dependent on the 
peptide substrate[44].   
Here, we analyze the deacetylase activity of HDAC1 constructs expressed from 
both bacterial and eukaryotic expression systems with peptide and protein substrates and 
reconstitute the core CoREST complex.  These studies demonstrate that protein-protein 
interactions in the CoREST complex enhance deacetylase activity by more than 10-fold. 
We additionally probed the effect of phosphorylation and phospho-mimic mutations in 
HDAC1 on the CoREST complex formation demonstrating that phosphorylation is not 
necessary to form protein interactions but does change substrate selectivity.  
Materials and Methods 
Reagents  
Amintra Maltose Binding Protein affinity resin was purchased from Expedeon (now 
Abcam). Ni-NTA agarose resin was purchased from Qiagen. Ni-sepharose fast flow 
prepacked columns were purchased from GE healthcare. Adenosine triphosphate (ATP), 
coenzyme A (CoA), NAD+, NADH, L-malic acid, malate dehydrogenase (MDH), citrate 
synthase (CS), and mouse monoclonal anti-polyhistidine-alkaline phosphatase antibody 
were purchased from Sigma. Rabbit monoclonal anti-HDAC1, anti-LSD1, and anti-
CoREST antibodies were purchased from Cell Signaling Technologies. N-terminally 
acetylated and C-terminally carboxylated, singly acetylated lysine peptides were 
purchased from Peptide 2.0 or Synthetic Biomolecules. 3% (v/v) acetic acid standard was 
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purchased from RICCA Chemical. All other materials were purchased from Fisher at 
>95% purity unless noted otherwise. 
Expression and Purification of HDAC1 
HDAC1 cDNA (BC00301) was purchased from Horizon Discovery. HDAC1 was 
cloned into a pFastBac vector with a N-terminal His-MBP tag[50], provided by Dr. Clay 
Brown at the Life Sciences Institute (LSI) Center for Structure Biology, using Gibson 
Assembly (New England Biolabs). HDAC1 was also cloned into a modified pET12a vector 
containing a N-terminal 6xHis-SUMO tag by restriction enzyme digestion (KpnI, N-
terminus, and XhoI, C-terminus). The 6x-His-SUMO-HDAC1 construct was further 
modified using site-directed mutagenesis to replace the two serines phosphorylated in 
vivo, S421 and S423, with glutamates to mimic phosphorylation. All primers are given in 
Table 3.1. Proper gene insertion and mutagenesis was confirmed using Sanger 
sequencing at the University of Michigan sequencing core.  
For insect expression, the High Throughput Protein Lab at LSI then expressed the 
His-MBP-HDAC1 in Tni insect cells grown in 2 L of serum free media at 27°C for 72 
hours[50]. The resulting pellet was resuspended in lysis buffer (50 mM Tris pH 8, 200 mM 
NaCl, 1 mM TCEP, 10% glycerol, 1% Tween-20). The cells were lysed by end over end 
rotation for 20 minutes at 4°C. The lysate was cleared by centrifugation at 30,000 x g, 45 
minutes, at 4°C. The cleared lysate was incubated with 5 mL of Amintra MBP Affinity resin 
pre-equilibrated with wash buffer (50 mM Tris pH 8, 200 mM NaCl, 1 mM TCEP, 10% 
glycerol) by end over end rotation for 2 hours. Using a gravity column, the lysate flow-
through was collected and the resin was washed with at least 20 column volumes (CVs) 
of wash buffer. The His-MBP-HDAC1 was eluted with 5 CVs of elution buffer (50 mM Tris 
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pH 8, 200 mM NaCl, 1 mM TCEP, 10% glycerol, 10 mM maltose). The presence of His-
MBP-HDAC1 was confirmed by SDS-PAGE with Coomassie staining. The sample was 
dialyzed into storage buffer (50 mM Tris pH 8, 200 mM NaCl, 1 mM TCEP, 10% glycerol) 
at 4°C overnight, followed by concentration using an Amicon 30K MWCO. The estimated 
purity was 80%. The concentration was determined under native conditions by A280 with 
the calculated extinction coefficient 122,050 M-1cm-1, aliquoted and flash frozen.  
For E. coli expression, pET21a containing either WT or the S421E/S423E 6x-His-
SUMO-HDAC1 was transformed into BL21(DE3) competent cells and the cells were 
plated onto LB-agar containing 100 g/mL ampicillin. A single colony was selected and 
used to inoculate a 2xYT starter culture containing 100 g/mL ampicillin. The starter 
culture was grown at 37°C, 250 rpm until cloudy, approximately 4-6 hours. 10 mL starter 
culture was then used to inoculate 1-L 2xYT containing ampicillin. The cells were grown 
at 37°C, 150-200 rpm, until the OD600 = 0.4-0.6. The cultures were cold-shocked on ice 
for 10 min and induced with 0.5 mM isopropyl -D-1-thiogalactopyranoside (IPTG). The 
cultures were grown for 16-18 hours at 18°C, 150-200 rpm. Harvested cells were 
resuspended in lysis buffer without detergent (50 mM Tris pH 8, 200 mM NaCl, 1 mM 
TCEP, 10% glycerol) and lysed using a microfluidizer (Microfluidics). The lysate was 
cleared as previously described for the insect purification. The cleared lysate was 
incubated with 5 mL of Ni-NTA resin pre-equilibrated with wash buffer by end over end 
rotation for 2 hours. Using a gravity column, the lysate flow-through was collected and the 
resin was washed with at least 20 CVs of wash buffer. The 6xHis-SUMO-HDAC1 was 
eluted using a stepwise imidazole gradient up to 500 mM. The resulting fractions were 
analyzed for HDAC1 by SDS-PAGE with Coomassie staining. Fractions containing 6xHis-
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SUMO-HDAC1 were dialyzed into storage buffer at 4°C overnight followed by 
concentration using an Amicon 30K MWCO centrifugal filter.  The estimated purity was 
50%. The protein concentration was determined using BCA assay (Thermo) with bovine 
serum albumin (BSA) standards, aliquoted and flash frozen.   
Expression and Purification of LSD1 
LSD1 cDNA (O60341) was purchased from Sino Biological. LSD1 was cloned into 
a pET28a vector with a N-terminal thrombin cleavable 6xHis tag by NdeI (N-terminal) and 
XhoI (C-terminal) restriction enzyme digest. Primers are given in Table 3.1. The plasmid 
was transformed into Rosetta2(DE3)-pLysS competent cells and the cells plated on LB-
agar containing 50 µg/mL kanamycin and 34 µg/mL chloramphenicol. A single colony was 
selected to inoculate a 20 mL 2xYT starter culture containing kanamycin and 
chloramphenicol. The starter culture was grown at 37°C, 200 rpm until cloudy. 2 L of 2xYT 
containing kanamycin and chloramphenicol was inoculated with the 20 mL culture and 
grown at 37°C, 200 rpm until the OD600 was 0.6. The flasks were cold-shocked for 10 min 
on ice, induced by addition of 0.2 mM IPTG and grown 16-18 hours at 16°C, 200 rpm. 
Harvested pellets were resuspended in lysis buffer without detergent, lysed using a 
microfluidizer and the lysate was cleared as previously described. Using a gravity column, 
the cleared lysate was added to 5 mL Ni-NTA resin preequilibrated with wash buffer. The 
column was washed with 10-20 CVs of wash buffer and the 6xHis-LSD1 was eluted with 
a stepwise imidazole gradient up to 500 mM. The resulting fractions were analyzed for 
LSD1 by SDS-PAGE and Coomassie staining. Fractions containing 6xHis-LSD1 were 
dialyzed into cleavage buffer (storage buffer containing 20 mM CaCl2) at 4°C overnight 
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followed by concentration using an Amicon 30K MWCO centrifugal filter, concentration 
determined by BCA assay, aliquoted and flash frozen. The estimated purity was 90%.  
Table 3.1: Primers for various construct cloning. Restriction enzymes sites are in bold italics. Mutagenesis 
sites are in bold/underlined.  



























Expression and Purification of CoREST 
A pET28a vector containing CoREST with a N-terminal thrombin cleavable 6xHis 
tag was generously provided by Prof. Wenshe Liu at Texas A&M University. 6xHis-
thrombin-CoREST plasmid was transformed into BL21(DE3) competent cells and cells 
plated onto LB-agar containing 50 g/mL kanamycin. Following transformation, the 6xHis-
thrombin-CoREST protein was expressed as previously described for 6xHis-LSD1.  
Following expression, 6xHis-thrombin-CoREST was purified as previously described for 
LSD1 but with the following alterations: the purification only used an imidazole gradient 
up to 200 mM and for concentration a 10K MWCO Amicon centrifugal filter was used. The 
estimated purity was 60%.  
Expression and Purification of LSD1-CoREST complex 
An additional pET15 vector containing LSD1 with a N-terminal thrombin cleavable 
6xHis tag was generously provided by Prof. Wenshe Liu at Texas A&M University. The 
pET15 LSD1 vector was co-transformed with the pET28 CoREST vector in BL21(DE3) 
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competent cells and cells plated onto LB-agar containing 100 g/mL ampicillin and 50 
g/mL kanamycin and expressed according to the previously described LSD1 protocol 
but with ampicillin and kanamycin selection. Harvested cells were resuspended and lysed 
as previously described. The cleared lysate was added onto a pre-packed 5 mL Ni-NTA 
column at 1 mL/min. The column was washed until the UV signal subsided. LSD1-
CoREST was then eluted using a linear gradient up to 500 mM imidazole. The resulting 
fractions were analyzed for LSD1-CoREST by SDS-PAGE with Coomassie staining. 
Fractions containing LSD1-CoREST were pooled and dialyzed overnight in cleavage 
buffer. Following dialysis, pooled fractions were analyzed by size exclusion 
chromatography, using a Superdex S200 analytical column equilibrated with dialysis 
buffer, to confirm the presence of the LSD1-CoREST complex. The pooled fractions 
containing LSD1-CoREST complex, at 80% purity, were concentrated using a 10K 
MWCO Amicon centrifugal filter.  
6xHis Tag Cleavage  
The 6xHis tag was cleaved using the Thrombin CleanCleave™ kit by Sigma 
following the manufacturer’s instructions with the following specifications. Briefly, 1-2 mg 
of protein was incubated with the thrombin agarose beads at room temperature for 3 
hours. The cleaved protein was added to a 1 mL prepacked Ni-FF column. The column 
was washed with 5 mL of lysis buffer. The resulting fractions were analyzed by SDS-
PAGE Coomassie. Fractions containing cleaved CoREST were pooled and concentrated. 




The various constructs of HDAC1 (6xHis-MBP-HDAC1, 6xHis-SUMO-HDAC1, 
and 6xHis-SUMO-HDAC1_S421E/S423E) and (6xHis-LSD1)-(6xHis-CoREST) were 
incubated overnight at a 2:1 molar ratio in phosphate buffered saline (PBS) with rotation 
at 4°C. LSD1 antibody was added at a 1:100 dilution and allowed to further incubated 
with rotation at 4°C for one hour. The sample was then added to Dynabeads™ Protein G 
(Thermo) and incubated with rotation at room temperature for 10 minutes. The beads 
were washed 3 times with 200 L PBS. The washed beads were transferred to a separate 
microtube and eluted with elution buffer (50 mM glycine pH 2.8) and SDS loading buffer 
(50mM Tris pH 6.8, 1% -mercaptoethanol, 0.0004% bromophenol blue, 6% glycerol, 2% 
sodium dodecyl sulfate). The samples were boiled at 95°C for 5 minutes. The eluted 
sample was run on an SDS-PAGE gel followed by semi-dry transfer onto nitrocellulose 
membrane. The membrane was blocked with 5% BSA in Tris Buffered Saline with Tween-
20 (TBST) for 45 minutes at room temperature with rocking. Primary antibodies 
corresponding to either HDAC1 (1:2000 dilution in TBST) or LSD1 and CoREST 
(together, 1:1000 and 1:500 dilution in TBST, respectively) was then incubated with the 
membrane for 90 minutes at room temperature with rocking. The membrane was washed 
for 5 minutes, 3 times with TBST. Goat anti-rabbit secondary conjugated to HRP 
(1:10,000 in TBST) was incubated with membrane for 60 minutes at room temperature. 
Following an additional washing step, the membrane was monitored for 
chemiluminescence using a ChemiDoc imager (BioRad) and SuperSignal™ West Pico 
PLUS chemiluminescent substrate (Thermo).  
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Preparation of Singly Acetylated Histone H3 
Singly acetylated Xenopus leavis histone H3 had been previously purified (as 
detailed in Castaneda et al.[51]) and stored as lyophilized protein at -20°C. Lyophilized 
H3 was resuspended in assay buffer (25 mM HEPES pH8, 137 mM NaCl, 5 mM KCl) at 
room temperature over 20 minutes with gentle agitation. Any insoluble particulate was 
removed by centrifugation at 10,000 x g for 5 minutes. Resuspended H3 was dialyzed 
overnight in assay buffer at 4°C using 3500 MWCO Slide-a-Lyzer™ dialysis cassettes 
(Thermo). The concentration of H3 sample following dialysis was determined by Bradford 
assay (Thermo) with bovine serum albumin (BSA) standards. The sample was then 
aliquoted and flash frozen.  
Coupled-enzyme Acetate Detection Assay 
Acetyl CoA Synthetase (ACS) was expressed and purified as previously 
described[52, 53].  
The coupled acetate-detection assay or simply the ‘acetate assay’ was performed 
as previously described with a few modifications[53]. Briefly, lyophilized peptides were re-
suspended in water. Peptide concentration was determined by the BCA assay. Reactions 
containing 100-500 M peptide or 10-30 M protein in assay buffer were initiated with 
0.1-1 μM HDAC1 at 37°C. Timepoints, 60 μL, were quenched with 5 μL of 10% 
hydrochloric acid and kept on ice. Timepoints were flash frozen with liquid nitrogen and 
stored at -80°C until work-up. 
Coupled solution (50 mM HEPES, pH 8, 400 μM ATP, 10 μM NAD+, 30 μM CoA, 
0.07 U/μL CS, 0.04 U/μL MDH, 50 μM ACS, 100 mM NaCl, 3 mM KCl, 50 mM MgCl2, and 
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2.5 mM L-malic acid) was prepared the day of the work-up and incubated at room 
temperature away from light for at least 25 minutes. Timepoints were thawed and 
neutralized with 15 μL of freshly prepared and filtered 6% sodium bicarbonate. 
Neutralized timepoints and each acetate standard, 60 μL, were added to 10 μL coupled 
solution in a black, flat-bottomed, half-area, non-binding, 96-well plate (Corning No. 
3686). The resulting NADH fluorescence (Ex 340 nm, Em 460 nm) was measured on a 
PolarStar fluorescence plate reader until the signal reached equilibrium. Using the acetate 
standard curve, the final fluorescence of each timepoint was converted to M acetate 
product and the initial velocity of the reaction was determined from the time-dependence 
of the appearance of acetate. The catalytic efficiency of the reaction (kcat/KM) was 










Deacetylase activity of recombinant HDAC1 is dependent upon substrate length 
Full-length human HDAC1 was initially expressed in Escherichia coli (E. coli), 
rEcHDAC1, however this enzyme was inefficient (kcat/KM < 0.5 M-1s-1) at catalyzing 
deacetylation of acetylated peptide substrates. Additionally, deacetylase activity against 
peptide substrates was not increased by preparing a mutant that contains two glutamate 
side chains mimicking proposed in vivo phosphorylation sites (Ser421Glu/Ser423Glu; 
phosphomimic mutant) shown to be important for activation of deacetylase activity[40]. 
Full-length human HDAC1 expressed in Tni insect cells, rTniHDAC1, and purified to 
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homogeneity contained increased deacetylase activity against peptide substrates (kcat/KM 
= 2.3 ± 0.3 M-1s-1; Figure 3.1-A). The HDAC1 expressed in insect cells was additionally 
shown to be phosphorylated using the Pro-Q™ Diamond phosphoprotein stain (Figure 
3.2). However, the increased deacetylase activity was still minimal, particularly compared 
to HDAC1 purchased from BPS Biosciences. To explore whether HDAC1 catalyzes 
deacetylation of protein substrates more readily due to additional interactions, as has 
previously been shown with HDAC8[51], we measured deacetylase activity using singly 






Figure 3.1: Deacetylation rate of recombinant HDAC1 varies with substrate 
A) Dependence of WT rTniHDAC1 reaction rate on the substrate concentration of a H3K9ac peptide 
analog (TKQTARK(ac)STGGKA) measured using the acetate assay. B) Dependence of WT rTniHDAC1 
reaction rate on substrate concentration of singly acetylated Histone H3 at Lys9 (H3 K9Ac). C) 
Comparison of catalytic efficiencies of HDAC1 constructs catalyzing deacetylation of Histone H3 
substrates. Exact values are given in Table 2. Bars represent the average value (N=2-4) with error bars 
representing S.D. Denoted p-values are calculated for comparison to the value of the commercially 






Figure 3.2: Detection of phosphorylated HDAC1 
A) Pro-Q Diamond Phosphoprotein stained SDS-PAGE gel. Lanes 1-2: Serial dilutions of WT rEcHDAC1 
(~55 kDa). Lane 3: empty. Lanes 4-8: Serial dilutions of MBP-rTniHDAC1 (~97 kDa). B) The same gel 
from A) stained with Coomassie following the fluorescent stain. Arrows indicate where to expect the 
bands based on the molecular weight. 
 
To measure deacetylase activity with an acetylated protein substrate, we used the 
acetate assay previously developed for peptide substrates[53] to measure the production 
of free acetate. We measured acetate production in reactions of HDAC1 with H3 
acetylated at lysine-9 (K9ac) with and without the potent inhibitor SAHA, where the 
presence of SAHA decreased the measured activity (<100 M-1s-1) demonstrating that the 
observed activity was catalyzed by HDAC1. Both the E. coli phosphomimic (PM) mutant 
and recombinant HDAC1 expressed in insect cells catalyze deacetylation of H3 K9ac 
more rapidly than the peptide analog. For rTniHDAC1, the increase is about 1000-fold 
(Figure 3.1-A vs. Figure 3.1-B), and the increase for the PM rEcHDAC1 was >5000-fold. 
Interestingly, the wild-type (WT) rEcHDAC1 did not display detectable deacetylase 
activity (kcat/KM < 0.05 mM-1s-1) using histone H3 K9ac. When the substrate scope was 
expanded to additional histone H3 acetylation sites, lysine-14 (K14ac) and lysine-23 







(K23ac), WT rEcHDAC1 catalyzed deacetylation of H3 K14ac at an observable rate 
(kcat/KM = 0.14 mM-1s-1). In comparison, the PM rEcHDAC1 had broader site selectivity 
and displayed measurable deacetylase activity towards H3 K9ac and H3 K23ac but not 
H3 K14ac indicating that the phosphomimic mutations altered substrate selectivity. WT 
rTniHDAC1 catalyzed deacetylation of all three H3 acetylation sites tested (Table 3.2).  
When the activity towards both peptide and protein substrates was compared to 
commercially available HDAC1, purchased from BPS Biosciences, all constructs were 
significantly less active (Figure 3.1-C). However, HDAC1 exists in multiple stable protein 
complexes in vivo[28-30], and these protein-protein interactions are proposed to enhance 
the activity of HDAC1[32]. The commercially available HDAC1 contains additional 
proteins that might enhance activity. In contrast, HDAC1 expressed in either insect cells 
or E. coli has fewer and/or different protein contaminants than the commercially available 
material (Figure 3.3). Previously HDAC1 has been purified in the respective in vivo 
complexes and demonstrated to have significant catalytic activity[33-35].  To test the 
function of the protein-protein interactions we were interested in reconstituting the minimal 
CoREST complex in vitro and analyze the effect of individual constituents of the complex 





Table 3.2: Catalytic efficiencies of HDAC1 constructs dependent on expression system  
 
kcat/KM (mM-1s-1)a 

















Peptided 0.0023±0.0003 0.034±0.005 <0.0001e n.dg <0.0001e n.dg 0.052±.015 
H3 
K9ac 
3.9±0.2 30±10 <0.05e 29±9 0.7±0.2 30±20 13±6 
H3 
K14ac 
0.29±0.02 18±6 0.14±0.05 15±7 <0.5e 20±10 17±5 
H3 
K23ac 
0.20±.02 30±20 <0.05e <5e 0.2±0.1 20±10 24±7 
aEach value is calculated as an average of initial velocities (N=2-4) at [substrate]= 15 M. The initial velocity was 
calculated from a stopped time course (n=3-4). Error represents S.E.M. calculated using GraphPad Prism analysis. 
b[HDAC1] = 1M. c[HDAC1] = 0.1M. d13-mer peptide based on H3 K9ac: TKQTAR(Kac)STGGKA eActivity could 





Figure 3.3: Coomassie-stained SDS-PAGE gel to illustrate purity of HDAC1 constructs. 
4g of protein was loaded per lane. The HDAC1 band is outlined with a black box. Lane 1 – commercially 
available HDAC1-FLAG (~56 kDa). Lane 2 – MBP-rTniHDAC1 (~96 kDa). Lane 3 – WT SUMO-
rEcHDAC1 (~67 kDa). Lane 4 – PM SUMO-rEcHDAC1 (~67kDa). The two outside lanes are molecular 
weight standards. 
 
HDAC1 interacts with LSD1-CoREST complex in vitro 
Full-length human LSD1 and full-length human CoREST were recombinantly 
expressed and purified from E. coli, both individually and together. 6xHis-LSD1 and 
6xHis-CoREST were confirmed to co-purify in a complex, hereby referred to as LSD1-
CoREST, by size-exclusion chromatography (SEC) (Figure 3.4). Only WT rTniHDAC1 
and PM rEcHDAC1 co-immunoprecipitated with LSD1 alone using a LSD1 antibody, 
though all constructs co-immunoprecipitated with LSD1-CoREST, demonstrating the 
formation of a complex (Figure 3.5). Attempts to identify a direct interaction between 
HDAC1 and CoREST by immunoprecipitation using the 6xHis-tag on HDAC1 were 






unsuccessful. Though phosphorylation has been proposed to be necessary for HDAC1 
complex formation[40], LSD1-CoREST was shown to co-immunoprecipitate with WT 
rTniHDAC1, WT rEcHDAC1, and PM rEcHDAC1. While the WT rTniHDAC1 was 
confirmed to be phosphorylated, the WT rEcHDAC1 does not possess this post-
translational modification (Figure 3.2). The importance of phosphorylation was apparent 
for affinity and/or stability of a HDAC1-LSD1 interaction. 
 
Figure 3.4: Chromatogram of LSD1-CoREST through size-exclusion chromatography 
Inset is a Coomassie stained SDS-PAGE gel with the fraction corresponding to the major peak 
highlighted with a box. The gel indicates there are only two bands present, the top band corresponds to 





Figure 3.5: Co-immunoprecipitation of HDAC1 using an LSD1 antibody 
Expected molecular weights: rTniHDAC1 96kDa, rEcHDAC1: 67kDa, LSD1: 92kDa, CoREST: 53kDa. 
A) Co-immunoprecipitation of HDAC1 incubated with LSD1. B) Co-immunoprecipitation of HDAC1 
incubated with LSD1-CoREST. aPM: phosphomimic, S421E/S423E.   
 
Addition of LSD1-CoREST enhances HDAC1 deacetylase activity 
The deacetylase activity of an HDAC1-LSD1-CoREST complex reconstituted by 
incubation of the subunits in vitro was determined with both peptide and protein 
substrates. WT rTniHDAC1 incubated with LSD1 or CoREST individually displayed no 
enhancement of deacetylase activity with peptide substrate Figure 3.6-A).  Similarly, no 
enhancement of activity was observed when both LSD1 and CoREST, purified 
individually, were incubated with HDAC1 (Figure 3.6-A). However, when WT rTniHDAC1 
was incubated with the pre-formed, co-purified LSD1-CoREST complex significant 
enhancement of deacetylase activity of peptide substrate was observed, comparable with 
the activity of commercially available HDAC1 (Figure 3.6-A). In contrast, the deacetylase 
activity of HDAC1 purified from E. coli with peptide substrates was not enhanced by 
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incubation with LSD1-CoREST. The catalytic activity of HDAC1-LSD1-CoREST was 
increased for deacetylation of acetylated H3 (Figure 3.6-B). For both insect and PM 
rEcHDAC1, the enhancement of activity applied to all tested acetylation sites. 
Interestingly, for the WT rEcHDAC1, activity was enhanced for only H3 K9ac and H3 
K14ac while activity for H3 K23ac not detectable (Table 3.2). There was no detected 
deacetylase activity of the LSD1-CoREST complex alone when tested with peptide or 
protein substrates. 
The extent of activation observed upon incubation with the LSD1-CoREST 
subcomplex varied with the acetylation site; the fold increase in activity ranged from 
approximately 10 to over 300-fold (Table 3.3). WT rTniHDAC1 and PM rEcHDAC1 
showed similar activation (within 2-fold) upon addition of the LSD1-CoREST subcomplex 
for the substrates H3 K9ac and H3 K23ac, although addition of LSC1-CoREST activated 
deacetylation of H3 K23ac 10-fold more than H3 K9ac. This trend was reversed for WT 
rEcHDAC1, with LSD1-CoREST activating deacetylase activity for H3 K9ac, but not H3 





Figure 3.6: Comparison of catalytic efficiencies of HDAC1 constructs in catalyzing acetylated Histone 
H3 substrates in the presence of protein interactors 
A) Comparison of the catalytic efficiency of WT rTniHDAC1 upon addition of LSD1 and CoREST, both 
individually (gray and black outline, respectively) and combined (blue outline: LSD1 and CoREST purified 
individually, blue: LSD1-CoREST co-purified in complex), and commercially available HDAC1 (green). 
Each bar is calculated from an initial velocity using stopped timepoints (n=4) at [S] = 200M, error bars 
represent the standard error calculated by GraphPad Prism analysis. B) Catalytic efficiencies calculated 
for HDAC1 incubated with the LSD1-CoREST subcomplex. Exact values are given in Table 3.2. Bars 
represent the average value (N=2-4) with error bars representing S.D. Denoted p-values (ns = not 
significant) are calculated for the comparison to the value of the commercially available HDAC1 (green) 






Table 3.3: Activation of deacetylase activity upon addition of LSD1-CoREST  
 
Ratio of Activity Activationa 
H3K9Ac H3K14Ac H3K23Ac 
Insect WT 8±3 60±20 200±100 
E. coli WT >500 110±60 n/a 
E. coli S421E/S423E 40±30 >400 100±70 
aCalculated using values from Table 3.2. The error of the ratios 
was calculated using propagation of uncertainty[55].  
 
Discussion 
We have performed kinetic characterization of recombinant HDAC1 with and 
without the known interacting proteins LSD1 and CoREST. To compare HDAC1 activity 
when alone versus present in complex, we aimed to reconstitute the CoREST complex in 
vitro. Using LSD1 and CoREST expressed separately and as a complex, we saw in vitro 
interaction with all HDAC1 constructs. The in vitro HDAC1-LSD1-CoREST complex 
displayed significantly enhanced deacetylation efficiency. The measured deacetylase 
activity was then comparable to commercially available HDAC1 indicating additional co-
purifying proteins present are important for enhancing HDAC1 deacetylase efficiency.  
HDAC1 substrate selectivity is dependent on post-translational modifications 
The analyzed substrates included both histone peptide analogs, and histone 
proteins selected due to being known substrates of HDAC1. Initially, HDAC1 expressed 
and purified out of the insect cells was the most active and was the only construct able to 
catalyze deacetylation of acetylated-peptide substrates. The WT rTniHDAC1 could have 
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additional post-translational modifications present that impact deacetylation efficiency, 
and we demonstrated that recombinant WT rTniHDAC1 is phosphorylated (Figure 3.2). 
We further explored the impact of phosphorylation on deacetylase activity by creating a 
phosphorylation mimic in E. coli using the negatively charged glutamate substitute for 
phosphorylated serine residues. The E. coli phosphorylation mimic still did not 
demonstrate significant deacetylase activity towards peptide substrates. Yet, we were 
able to detect deacetylase activity of all constructs towards histone protein substrates. 
The insect WT HDAC1 deacetylated all histone acetylation sites. The phosphorylation 
mimic HDAC1 expressed in E. coli demonstrated broader substrate selectivity by 
deacetylating two acetylation sites (H3 K9ac and H3 K23ac) compared to wild type 
HDAC1 expressed in E. coli that catalyzed deacetylation of a different acetylation site (H3 
K14ac) (Table 3.2). When compared to the HDAC1 expressed in insect cells, the proteins 
expressed in E. coli each had similar activity (~2-fold) for one of the acetylation sites (H3 
K23ac for the PM and H3 K14ac for the WT) yet were much less active for other 
acetylation sites (~4-60 fold).  
HDAC1 substrate selectivity is dependent on complex formation  
When alone, WT rTniHDAC1 and PM rEcHDAC1 displayed similar substrate 
selectivity with greatest activity towards H3 K9ac and less activity towards H3 K14ac and 
H3 K23ac (Figure 3.7-A). Upon addition of LSD1-CoREST, both constructs then 
displayed similar activity for all H3 acetylation sites (Figure 3.7-B). Interestingly, WT 
rEcHDAC1 in the presence of LSD1-CoREST had similar activity to WT rTniHDAC1 
towards H3 K9ac and H3 K14ac, but still had no detectable deacetylase activity towards 
H3 K23ac (Figure 3.7-B). Similar activity for H3 K23ac for WT rTniHDAC1 and PM 
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rEcHDAC1 seems to indicate the K23ac site is specific to phosphorylated HDAC1. The 
overall similarity in substrate selectivity for the phosphomimic expressed in E. coli and the 
phosphorylated HDAC1 expressed in insect cells is encouraging, as it suggests the 
phosphomimic can be successfully used to probe HDAC1 activity and selectivity.   
 
Figure 3.7: Substrate selectivity of HDAC1 constructs. 
A) Deacetylase activity of HDAC1 alone against acetylated histone H3. B) Deacetylase activity of HDAC1 
in the presence of LSD1-CoREST against acetylated histone H3.  
 
These results suggest that HDAC1 depends on the primary amino acid sequence 
for recognition of substrates and catalytic activity. Histone H3 in this study was alone in 
solution, which does not occur biologically as Histone H3 is found in more structured 
tetramers with Histone H4[56]. Further studies of deacetylation of the histone H3/H4 
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tetramer, the histone H3/H4/H2A/H2B octamer, and the nucleosome (octamer with DNA) 
would be useful to elaborate on the observed activation differences. The nucleosome is 
especially a key interest as there have been conflicting studies of which component of the 
complex interacts with the nucleosome allowing deacetylation, LSD1[34] or CoREST[57].  
Interactions significantly enhance HDAC1 deacetylase activity 
This work concretely shows that the presence of the LSD1-CoREST subcomplex 
significantly increases HDAC1 deacetylase activity and, possibly, alters selectivity. An 
important distinction is that both LSD1 and CoREST are necessary to enhance HDAC1 
deacetylase activity; this activation was achieved by co-purifying LSD1 and CoREST as 
a complex from recombinant expression in E. coli. CoREST consists of two distinct SANT 
domains, SANT1 on the N-terminus and SANT2 on the C-terminus. The ELM2/SANT1 
domain of CoREST has been established as necessary for HDAC1-CoREST 
interaction[30]. And the SANT2/Linker domain of CoREST has an established interaction 
with the tower domain of LSD1 as characterized by X-ray crystallography[58]. Recent 
structural studies indicate that the full CoREST complex forms via the LSD1 tower and 
CoREST linker domains, and CoREST has an additional contact with HDAC1 via its 
ELM2/SANT1 domain[34]. Our data indicate that the tower domain of LSD1 interacts 
directly and independently with phosphorylated HDAC1, as shown by the co-
immunoprecipitation of HDAC1 and LSD1 (Figure 3.8). However, the formation of the 
CoREST-LSD1 subcomplex is required for the interaction of CoREST with HDAC1 and 
to enhance HDAC1 deacetylation (Figure 3.8). This is shown by the absence of co-
immunoprecipitation of HDAC1 and CoREST and the lack of activity enhancement of 
HDAC1 upon addition of CoREST. Interestingly, the interaction of the LSD1-CoREST 
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subcomplex is not dependent on HDAC1 phosphorylation. We are unable to determine if 
these interactions differences are dependent on different binding affinities of 
phosphorylated and unphosphorylated HDAC1 to LSD1 versus LSD1-CoREST. 
Crosslinking studies indicate the region of HDAC1 containing the phosphorylation sites 
interacts with both LSD1 and CoREST [34]. The additional interaction points enabled by 
CoREST could be enough to overcome weaker interaction points with LSD1.Further 
exploration into the binding affinities and formation constants for the different HDAC1 
constructs would help elucidate the importance of HDAC1 phosphorylation in vivo. 
 
Figure 3.8: Proposed formations of HDAC1, LSD1, and CoREST containing complexes 
 
Successful in vitro reconstitution of a HDAC1-containing complex will allow further 
exploration of how these complexes are assembled. The CoREST complex is known to 
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be involved in gene transcription regulation due to its interactions with histones, and the 
core components are known to be important for cell differentiation and cell cycle 
regulation, making these proteins valuable cancer therapeutic targets[59]. The core 
components of the complex are an HDAC (either HDAC1 or HDAC2), LSD1, and 
CoREST[59]. The core CoREST complex explored here could be further expanded to 
include other known protein interactors, such as HDAC2. The addition of other 
interactions may further alter the activity and selectivity of the CoREST complex. It is 
established histone tails are known substrates for HDAC1-containing complexes and it is 
worthwhile to continue establishing the activity and selectivity for histone substrates, 
however the NuRD HDAC1 complex has been found to deacetylase non-histone proteins, 
such as p53[13]. The exploration of how complexes affect selectivity towards non-histone 
substrates is valuable to further understand HDAC1 involvement in biological processes. 
Furthermore, the use of bacterially expressed enzyme allows analysis of unmodified 
enzyme in addition to incorporating specific post-translational modifications, which is 
harder to control in eukaryotic expression systems. Understanding the formation of these 
complexes and how they are regulated in their cellular environment will ultimately 
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Chapter 4 : Structure-based Prediction of Substrate Selectivity of HDAC6‡ 
 
Introduction 
For cells and organisms to survive and adapt to different conditions, complex and 
fine-tuned, context-dependent regulation is crucial. Much of this regulation is achieved by 
post-translational modifications (PTM) that can change the behavior of a protein. One of 
the major regulatory modifications is acetylation and subsequently deacetylation. Histone 
deacetylases, HDACs, catalyze the removal of an acetyl group from the post-translational 
modification of acetyl-lysine in proteins. They are divided into two major groups, zinc-
dependent HDACs and NAD-dependent HDACs called sirtuins. Zinc-dependent HDACs 
are further divided into subclasses based on their homology to yeast enzymes[1].  
Histone deacetylase 6 (HDAC6) is a class IIB deacetylase and is the only HDAC 
to contain two deacetylase domains with distinct specificities. The first domain specifically 
catalyzes deacetylation of acetylated C-terminal lysine residues[2], while the second 
domain shows broad substrate selectivity[3]. HDAC6 is primarily localized to the  
cytoplasm and HDAC6 deacetylase activity has been linked to several cytoplasmic  
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cellular processes: microtubule stability and cell motility through deacetylation of -
tubulin[4]; lysosome and autophagosome fusion by cortactin deacetylation[5]; protein 
folding by regulation of Hsp90 activity[6, 7]; innate immunity via deacetylation of retinoic 
acid inducible gene-I protein; and aggresome formation using HDAC6’s ubiquitin binding 
domain[8]. While the broad specificity of HDAC6 has been reported, an understanding of 
the selectivity determinants is still lacking, as is a detailed understanding of the underlying 
structural basis that makes this particular HDAC more promiscuous than others, such as 
HDAC8[9].  
Many of the enzymes that install or remove PTMs act on short linear motifs (SLIMs) 
that are often exposed. Therefore, their substrate selectivity may be approximated by 
short peptides that mimic the region[10]. Different types of prediction methods for finding 
putative substrates have been developed. Many sequence-based predictions find 
modification sites based on position-specific scoring matrices (PSSMs)[11], that are 
derived from a large set of substrates. However, these do not account for possible 
interdependencies between amino acids at different positions in the substrate, nor do they 
include secondary structure elements that might be important for recognition. Machine 
learning-based approaches can be used for these aims (e.g. HMMs[12] and naive 
Bayes[13]), but such approaches depend on considerable amounts of data.  
Structure-based methods can complement sequence-based methods, in cases of 
non-canonical motifs, as we have previously shown in the case of the PTM enzymes 
protein farnesyltransferase (FTase)[14] and HDAC8[9]. This approach assumes that the 
local peptide sequence of the substrate is a main determinant of selectivity. Our 
framework to assess substrate selectivity, Rosetta FlexPepBind[15], consists of 
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calibrating a protocol by generating structural models of the interaction of candidate 
substrates with the enzyme[16] and using this model to evaluate their respective binding 
affinity. The underlying assumption is that by properly defining and reinforcing the 
catalytically competent substrate binding conformation, the estimated binding ability can 
be taken as a proxy for substrate reactivity. Accuracy of the calibrated protocol can be 
estimated by applying it to an independent test set and then using it on candidate peptides 
with unknown activity to identify new substrates. 
In this study we utilized an accurate biochemical assay that measures acetate 
production following deacetylation[17] to quantify the catalytic activity of HDAC6 for 
specific peptides and to establish a gold standard set of peptide substrates. Based on 
these activities, we calibrated the structure-based approach FlexPepBind to evaluate 
activity of potential substrates. Calibration revealed important structural differences 
between HDAC6 and HDAC8 that form the basis of the considerable difference in 
selectivity of these two deacetylases. Finally, application of this method to screen the 
acetylome identified novel potential regulatory mechanisms based on HDAC6-dependent 
regulation. 
 
Materials and Methods 
Reagents 
High flow amylose resin was purchased from New England Biolabs and Ni-NTA 
agarose was purchased from Qiagen. Adenosine triphosphate (ATP), coenzyme A (CoA), 
NAD+, NADH, L-malic acid, malate dehydrogenase (MDH), citrate synthase (CS), and 
mouse monoclonal anti-polyhistidine-alkaline phosphatase antibody were purchased 
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from Sigma. Boc-Lys-AMC was purchased from Bachem. N-terminally acetylated and C-
terminally carboxylated, singly acetylated peptides were purchased from Peptide 2.0 or 
Synthetic Biomolecules. 3% (v/v) acetic acid standard was purchased from RICCA 
Chemical. All other materials were purchased from Fisher at >95% purity unless noted 
otherwise. 
HDAC6 Expression and Purification 
The plasmids and protocols for the expression and purification of zebrafish HDAC6 
catalytic domain 2 (zCD2, residues 440-798) and both catalytic domains (zCD12, 
residues 60-798) were generously provided by David Christianson (University of 
Pennsylvania). HDAC6 zCD2 was expressed and purified as described previously[18]. 
HDAC6 zCD12 was expressed and purified as previously described with several 
alterations for expression optimization[3]. Briefly, zCD12 was expressed in E. coli 
BL21(DE3) cells grown in 2xYT in the presence of 50 mg/L kanamycin. Cells were grown 
at 37°C until the OD600=1.0, then cooled for 1 h to 16°C. The media was supplemented 
with 200 M zinc sulfate 30 min before induction with 75 M isopropyl -D-1-
thiogalactopyranoside (IPTG). Cells were harvested after 18 h and purified according to 
the zCD2 protocol[18]. The concentration of zCD12 was confirmed by an active site 
titration with tubastatin A using the Fluor de Lys assay (see below). Various 
concentrations of tubastatin A (0.025-2 M) were added to 50 M Boc-Lys-AMC peptide 
and the reaction was initiated by addition of ~0.1M HDAC6 (as determined by A280, ext. 
coeff. = 85,260 M-1cm-1) at 30°C. A control reaction was also performed without tubastatin 
A. The rate of each inhibitor reaction was compared to the control reaction to obtain the 
quantity of remaining activity (%). Using GraphPad prism, the % remaining activity was 
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plotted versus inhibitor concentration to determine the stoichiometric point of saturation 
where [inhibitor]=[enzyme].  
Coupled Acetate-Detection Assay 
Acetyl CoA Synthetase (ACS) was expressed and purified as previously 
described[17, 19].  
The coupled acetate-detection assay or simply the ‘acetate assay’ was performed 
as previously described with a few modifications[17]. Briefly, lyophilized peptides were re-
suspended in water when possible or with minimal quantities of acid, base, or organic 
solvent required to improve solubility. Peptide concentration was determined by one or 
more of the following methods: measuring A280 using the amino acid extinction 
coefficients if the peptide contained a tryptophan or tyrosine; using the fluorescamine 
assay if the peptide contained a free lysine[20];  performing the bicinchoninic (BCA) assay 
using bovine serum albumin (BSA) as a standard; or determining the concentration of 
acetate produced by complete deacetylation by HDAC6.  
Reactions containing 10-2000 μM singly acetylated peptides in 1X HDAC6 assay 
buffer (50 mM HEPES, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2) were initiated 
by addition of 0.1-1 μM HDAC6 at 30°C. At various time points a 60 μL aliquots were 
quenched with 5 μL of 10% hydrochloric acid and kept on ice until assay completion (no 
more than 90 minutes). Timepoints were flash frozen with liquid nitrogen and stored at -
80°C until work-up. 
Coupled solution (50 mM HEPES, pH 8, 400 μM ATP, 10 μM NAD+, 30 μM CoA, 
0.07 U/μL CS, 0.04 U/μL MDH, 50 μM ACS, 100 mM NaCl, 3 mM KCl, 50 mM MgCl2, and 
2.5 mM L-malic acid) was prepared the day of the assay work-up and incubated at room 
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temperature away from light for at least 25 minutes. Assay aliquots were quickly thawed 
and neutralized with 15 μL of freshly prepared and filtered 6% sodium bicarbonate. 
Neutralized timepoints or controls (acetate or NADH standards), 60μL, were added to 10 
μL coupled solution (or 1X assay buffer for NADH standards) in a black, flat-bottomed, 
half-area, non-binding, 96-well plate (Corning No. 3686). The resulting NADH 
fluorescence (Ex 340 nm, Em 460 nm) of standards and timepoints was read on a 
PolarStar fluorescence plate reader at 1-3-minute increments until the signal reached 
equilibrium. The standard curve for the acetate controls was compared to the NADH 
standards to verify assay function. When possible, a positive control reaction for enzyme 
activity was included. Using the acetate standard curve, the fluorescence of each 
timepoint was converted to μM product, and the dependence of the initial rate of the 
reaction (<10%) on the substrate concentration was measured. Using GraphPad Prism, 
the Michaelis-Menten equation (Equation 4.1) was fit to the resulting dependence of the 
initial velocity on substrate concentration to determine the kinetic parameters kcat/KM, kcat, 
and KM. Standard error was calculated using GraphPad Prism analysis. 25 peptides were 







 Equation 4.1 
Fluor de Lys Assay 
Reactions containing 25-200 M Boc-Lys-AMC peptide in 1X HDAC6 buffer were 
initiated with 0.01-0.1 M HDAC6. Various aliquoted timepoints (5 L) were quenched in 
individual wells of a Corning 3694 96-well half area microplate containing 45 L quench 
solution (0.73% Developer II, 1.2 M trichostatin A, 1X HDAC6 buffer). After a 10-minute 
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room temperature incubation, the fluorescence of the remaining substrate (Ex 360 nm, 
Em 362 nm) and the resulting product (Ex 360 nm, Em 460 nm) was determined using a 
PolarStar plate reader. Standard curves were made for each substrate concentration to 
reflect the change in product/substrate fluorescence ratio. Using these standard curves, 
each reaction timepoint was converted to μM product, and initial rate of the reaction 
(<10%) was measured at various substrate concentrations. Using GraphPad Prism, the 
Michaelis-Menten equation (Equation 4.1) was fit to the resulting dependence of the 
initial velocity on substrate concentration to determine the kinetic parameter kcat/KM. 
Calibration of FlexPepBind 
Running FlexPepBind requires the creation of a starting structure to generate a 
template (or a set of templates, as in the present study) for threading peptides. We used 
the structure of HDAC6 catalytic domain 2 from PDB (Protein Data Bank[21]) (CD2; PDB 
ID 5EFN) which was crystallized in a complex with a coumarin-linked trimer peptide 
substrate. In every described Rosetta protocol, we used Rosetta v2020.28. The protocol 
implemented in this study is like the one used in our previous study on HDAC8 
specificity[9], and in the following we mainly highlight the differences.  
To enforce a catalytic-competent binding conformation we defined constraints that 
characterize substrate binding as given by the solved structures of HDAC6 bound to 
ligands. Constraints were defined for Rosetta runs as done with HDAC8[9]. These include 
(1) interactions coordinating the proper binding of the Zn2+ ion required for enzymatic 
activity, (2) interactions between the acetylated lysine side chain and the binding pocket, 
and (3) a dihedral angle constraint in the peptide between residues 3 and 4 (i.e., adjacent 
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to the acetylated lysine in the modeled hexamers) to enforce a cis-peptide bond. All the 
distances between interacting residues were measured on structure PDB ID 5EFN. 
The best substrate peptide (sequence: EGKAcFVR) was built in the binding pocket 
using the corresponding atoms of trichostatin A. The rest of the peptide was added in an 
extended conformation. FlexPepDock was run on this structure with the constraints 
added, generating nstruct=1000 decoys with different setups. In contrast to the HDAC8 
study, here we selected not only the top-scoring structure, but rather the top 5 structures, 
according to the measures I_sc or reweighted_sc, depending on the protocol (Protocols 
Pxa and Pxb, respectively). Every peptide of the training dataset was threaded onto these 
starting structures using the Rosetta fixbb protocol and running FlexPepDock with 
minimization only. For each peptide sequence, the best score (reweighted_sc) among the 
5 templates was used to reflect its substrate strength (final scoring according to I_sc 
resulted in inferior predictions and was therefore not followed up).For protocols P1x & 
P2x, the receptor backbone was not moved, or only minimized, respectively. Since these 
protocols did not yield satisfactory predictions, for protocols P3x and P4x, the template 
was optimized using loop modeling prior to the peptide docking step. Loop modeling was 
performed with kinematic closure with fragments protocol [22] on the loop of residues 
455-467 (Figure 4.2). Fragments were generated as described in the fragment picker 
application manual and 1000 decoys were generated with the loop modeling protocol. 
The top (top2) scoring decoys were selected for protocol P3 (P4) to accommodate 
different possible loop and peptide conformations. 
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Running the calibrated protocol on the acetylome 
The dataset of the human acetylome was extracted from the PhosphoSitePlus 
database[23] (downloaded on 23/09/2020). Hexamer peptides around acetylated sites on 
human proteins with at least one low-throughput experiment to support were derived with 
two leading and three trailing residues around the modification site. Only peptides 
spanning a full hexamer (i.e., the modification is not at the termini) were selected. 
Interaction data for HDAC6 was downloaded from BioGRID[24] on 11/09/2020 from 
database version 4.1.190. For pathway analysis, we used Reactome with Pathway 
Browser version 3.7 and database release 74. 
 
Results 
Measurement of HDAC6 zCD2 substrate selectivity 
We used an enzyme-coupled acetate-detection assay, or simply the ‘acetate 
assay’ (see Methods), developed and used previously[9, 17], to measure the catalytic 
efficiency (kcat/KM) of HDAC6 catalyzing deacetylation of acetylated peptides.  These 
peptides included sequences from known HDAC6 substrate proteins, as well as a set of 
selected peptides with reported acetylation sites that were used in previous studies[9, 25, 
26]. We analyzed the substrate selectivity of the second deacetylase domain (CD2) of 
Danio rerio HDAC6 for these experiments which is more stable and has been shown to 
be a valid substitute for human HDAC6[3]. To ensure an accurate determination of kcat/KM 
we measured HDAC6-catalyzed deacetylation at a minimum of four peptide 
concentrations, with at least two concentrations below KM (Figure 4.1, squares). A total 




Figure 4.1: Dependence of deacetylation rate on substrate concentration for two representative peptides 
catalyzed by HDAC6. 
The initial velocity for each substrate concentration was determined by taking a linear regression of a 
time course consisting of a minimum of three timepoints, error bars reflect the standard error. The kinetic 
parameters are determined from a nonlinear least square fit of the Michaelis-Menten equation to the data 
and are listed in Table 1.  Black squares: example of data which met the criteria to produce accurate 
kcat/KM values. Open circles: example of overfit data resulting in calculation of a lower limit for kcat/KM, 
due to the KM being lower than the detection limit of the assay. 
 
Additionally, we included 15 peptides (set D-EXT, Table 4.2 above line) where the 
value of kcat was measured accurately but the KM value was lower than the limit of 
detection for the acetate assay (~10-20 μM substrate, Figure 4.1) allowing determination 
of only a lower limit for the value of kcat/KM. The measured kcat/KM values span the range 
of three orders of magnitude. We defined a cutoff of kcat/KM=104 M-1s-1 to distinguish 7 
non-substrates from the rest. Two additional peptides were tested but were not included 





Table 4.1: Kinetic parameters of peptide substrates used to construct the model (D-TRAINING).   














EG(K-Ac)FVR  LMNA (K450ac) 220,000 ± 40,000 4.2 ± 0.7 19 ± 4 
SD(K-Ac)TIG  
TUBA1A, TUBA4A, TUBA3E, 
TUBA1C, TUBA1B, TUBA4A 
(K40ac) 
70,000 ± 30,000 2.1 ± 0.3 29 ± 15 
AM(K-Ac)HRS  MYO1G (K90ac) 63,000 ± 9,000 1.9 ± 0.2 30 ± 7 
LA(K-Ac)EMK  CFAP157 (K35ac) 60,000 ± 20,000 1.4 ± 0.2 20 ± 10 
TG(K-Ac)TVA  TCOF1 (K146ac) 50,000 ± 10,000 1.37 ± 0.09 27 ± 7 
RT(K-Ac)SGD  ARHGEF1 (K234ac) 47,000 ± 9,000 1.5 ± 0.2 32 ± 9 
SQ(K-Ac)KTF  GRP94 (K682ac) 44,000 ± 9,000 1.6 ± 0.1 40 ± 10 
AG(K-Ac)RIA  DIP2A (K50ac) 40,000 ± 10,000 1.9 ± 0.5 50 ± 30 
YK(K-Ac)FYE  HSP90A (K436ac) 40,000 ± 10,000 1.8 ± 0.6 21 ± 9 
YG(K-Ac)LRK  ACTN1 (K195ac) 31,000 ± 4,000 6 ± 0.7 200 ± 80 
EG(K-Ac)TNY ZNF587 (K209ac) 29,000 ± 7,000 2 ± 0.4 70 ± 30 
QK(K-Ac)VKE ZNF280D (K209ac) 28,000 ± 6,000 1.8 ± 0.2 60 ± 20 
YE(K-Ac)EKE KIF5A, KIF5C (K348ac); KIF5B 
(K346ac) 27,000 ± 5,000 1.8 ± 0.1 60 ± 10 
EG(K-Ac)TGE ZKSCAN1 (K310ac) 25,000 ± 4,000 1.07 ± 0.08 43 ± 9 
LS(K-Ac)KSK PARP1 (K209ac) 24,000 ± 3,000 1.7 ± 0.2 70 ± 20 
PA(K-Ac)ESP ATBF1 (K3416ac); treacle 
(K904Ac) 22,000 ± 4,000 1.08 ± 0.05 49 ± 9 
AM(K-Ac)KIR CDK1 (K33ac) 16,000 ± 2,000 0.98 ± 0.09 60 ± 10 
QY(K-Ac)KEL LMNA (K260ac) 13,200 ± 700 1.58 ± 0.08 120 ± 10 
KT(K-Ac)PIW HSP90A (K294ac) 12,000 ± 2,000 0.8 ± 0.1 60 ± 20 
AH(K-Ac)RGS DDP3 (K294ac) 9,000 ± 3,000 >1 >150 
KL(K-Ac)KKE MYH1 (K1085ac) 6,000 ± 1,000 0.50 ± 0.09 90 ± 30 
EV(K-Ac)KMT MAP4 (K847ac) 5,600 ± 800 0.19 ± 0.02 35 ± 7 
GY(K-Ac)KTK RPL4 (K162ac) 5,000 ± 2,000 2.3 ± 0.5 400 ± 200 
AH(K-Ac)KSH S100AB (K84ac) 4,700 ± 400 >0.5 >100 
PL(K-Ac)KDR RPL3 (K393ac) 2,100 ± 200 >0.5 >200 
SW(K-Ac)DGL ACTN2 (K181ac) 1,200 ± 300 >0.3 >200 
aPeptides above the line were labeled as substrates, below the line were labeled as non-substrates 
(cutoff = 10,000 M-1s-1). bValues (mean ± standard error) were calculated using Equation 4.1 from initial velocities 
(n=3-4) from 4 substrate concentrations with 0.1-0.5M HDAC6.  
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Table 4.2: List of peptides where only a lower limit for kcat/KM was determined (D-EXT).   














YD(K-Ac)DEV  SIRT1 (K430ac) >110,000 0.28 ± 0.04 <25 
ME(K-Ac)FKI  XPOT(K627ac) >80,000 2.0 ± 0.5 <25 
ET(K-Ac)YRW  VDAC1 (K61ac) >70,000 4 ± 1 <50 
GG(K-Ac)RVM  VPS35 (K35ac) >60,000 1.4 ± 0.2 <25 
YD(K-Ac)LRK  ACTN4 (K214ac); TUBG1 (K397ac) >50,000 1.2 ± 0.2 <25 
HG(K-Ac)EVG  PCPB1 (K23ac, K57ac) >40,000 2.2 ± 0.5 <50 
QG(K-Ac)SGN  MYO18B (K401ac) >40,000 1.1 ± 0.2 <25 
ID(K-Ac)RTI  EEF1A1 (K31ac), EEF1A2, 
EEF1A1P5 (K36ac) >40,000 1.0 ± 0.2 <25 
GA(K-Ac)DEP  TCOF1 (K1414ac) >40,000 0.9 ± 0.2 <25 
VS(K-Ac)RKL  UBA1 (K1024ac), ARHGAP32 
(K674ac) >40,000 1.0 ± 0.1 <25 
YE(K-Ac)FRN USP32 (K209ac) >40,000 1.1 ± 0.2 <25 
MK(K-Ac)LKE PASD1 (K379ac) >30,000 0.7 ± 0.1 <25 
SQ(K-Ac)YKR MART3 (K473ac) >30,000 1.3 ± 0.4 <50 
CG(K-Ac)GLE CSRP1 (K151ac) >20,000 1.1 ± 0.4 <50 
SE(K-Ac)ILQ TCOF1 (K294ac) >20,000 1.2 ± 0.2 <50 
EG(K-Ac)GNG EIF5 (K28Ac) >17,000 0.84 ± 0.09 <50 
ME(K-Ac)KKE GBP7 (K389Ac) 3,300 ± 200c >0.3c >150c 
QD(K-Ac)PLR CCDC86 (K261Ac) >2,000 0.11 ± 0.04 <50 
aThe peptides listed below the line were not used for further analysis for the substrate model. bValues (mean ± 
standard error) were calculated from initial velocities (n=3-4) from 4 substrate concentrations. cValues were 
calculated from initial velocities (n=3-4) from 3 substrate concentrations.  
Structure-based computational prediction identifies most substrates of HDAC6 
The calibration of FlexPepBind was performed using the kcat/KM values for HDAC6-
catalyzed deacetylation of hexamer peptides (Table 4.1, hereinafter referred to as D-
TRAINING), using an approach similar to the one previously applied to HDAC8 and 
FTase enzymes[9, 14]. First, the best measured substrate of HDAC6 (EGKAcFVR, derived 
from prelamin) was docked using Rosetta FlexPepDock[9] into the binding pocket of a 
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solved CD2 HDAC6 structure. Peptides from the D-TRAINING set were then threaded 
onto this template set and minimized (see Methods). The top-scoring model (according 
to reweighted score) was used as an estimate for their binding ability (Protocols BASIC_I 
and BASIC_R in Table 4.3). The performance of the protocol was evaluated based on 
the calculated binary distinction (AUC values) and correlation between experimental 
values and Rosetta scores (Pearson correlation).  
Table 4.3: Different FlexPepBind protocols evaluated in this study. 







BASIC_I - - interface score 
BASIC_R - - reweighted score 
RMIN_I ✓ - interface score 
RMIN_R ✓ - reweighted score 
RLOOP_I - ✓ interface score 
RLOOP_R - ✓ reweighted score 
RLOOPS_I - ✓✓ interface score 
RLOOPS_R - ✓✓ reweighted score 
 
Using the standard protocols, BASIC_I and BASIC_R, resulted in low AUC values 
and no correlation between the experimental values of our dataset and the Rosetta scores 
(reweighted score). We note that using a similar protocol we were able to achieve 
excellent distinction in our previous study of HDAC8 substrate selectivity[9].  Examination 
of possible differences between the structures of HDAC6 and HDAC8 highlighted a 
significantly longer loop in HDAC6 (455-467) near the binding site that might rearrange 
for substrate binding (Figure 4.2). We therefore first ran the same protocol with receptor 
backbone minimization in the refinement step for template generation (corresponding 
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protocols RMIN_I and RMIN_R). This allowed the loop to move away from the binding 
site, opening it up. This slight modification in the protocol resulted however only in a slight 
improvement of correlation to experimental values, while the binary distinction did not 
change much. 
 
Figure 4.2: Key differences in the substrate binding structure between HDAC6 and HDAC8 
Note the different loop structures (orange/magenta) and the difference in a key residue which forms a 
hydrogen bonding to the substrate and is shown in stick structure (Ser531 magenta, Asp101 orange). 
Both structures contain trichostatin A bound to the metal ion (dark gray). Green/orange: HDAC8 (PDB 
ID 1t64). Cyan/magenta: HDAC6 CD2 (PDB ID 5eek). 
 
We proposed that additional receptor loop flexibility might improve the 
performance of our protocol. To test this, we modelled this loop (455-467) using the 
Rosetta kinematic loop closure with fragments protocol ([22], generating 1000 models; 
see Methods). We picked the top-scoring model and repeated the above protocol 
involving docking the best substrate peptide into the binding pocket, and threading 
different candidate substrates onto top-scoring models (protocols RLOOP_I and 
RLOOP_R, respectively). By using starting structures from this setup, we were able to 
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obtain good performance for the D-TRAINING set (Table 4.4 and Figure 4.3). When 
selecting among a set of loop structures obtained from loop modeling (protocol 
RLOOPS_I), the results did not improve further. Loop flexibility is crucial for selectivity 
prediction as these were the only models to provide good correlations.  
Table 4.4: Performance metrics of the top 3 protocols on the D-TRAINING dataset (25 peptides)  
































-0.41 [0.035] -0.57 [0.003] 
aSpecificity measures the proportion of negatives correctly identified. bSensitivity measures the proportion of positives 
correctly identified. cMatthew correlation coefficient. dArea under the ROC curve.  
We first tested our protocols on dataset D-EXT, since our measurements indicated 
that these peptides are substrates, although accurate kcat/KM values could not be 
determined due to low KM values (Table 4.2). We found that even though the RLOOP_I 
protocol performed best for D-TRAINING in terms of AUC and correlation values, it 
predicted that most of these peptides were non-substrates (Figure 4.3-A, depicted with 
triangles). Therefore, to reduce the number of false negatives, we moved forward with 
protocol RLOOP_R, which showed similar performance on the D-TRAINING set (Figure 
4.3-B,-E and Table 4.4). To define substrates, we defined two cutoffs: -890 gives the best 
value by the Youden index (Y = specificity + sensitivity - 1), while the stricter cutoff of -














Figure 4.3: Performance of different protocols on the D-TRAINING set. 
(A-C) Correlation plots between experimental (y-axis, logarithmic scale) and predicted substrate 
activities (x-axis). (A) Protocol RLOOP_I (cutoff: -870), (B) Protocol RLOOP_R (cutoff: -890, dotted 
dashed line), (C) Protocol RLOOPS_I (cutoff: -880, dotted dashed line. Strict cutoff: -900, dashed line). 
Circles: D-TRAINING dataset; triangles: D-EXT (presented on edge due to only having lower limits). (D-
E) Area Under the Curve (AUC) plots for the three protocols (RLOOP_I, RLOOP_R and RLOOPS_I; 
solid, dashed and dotted line, respectively), reflecting the ability to distinguish between substrates and 
non-substrates. (D) D-TRAINING set (25 peptides) (E) D-TRAINING + D-EXT (25 + 16 peptides). 
Predictions on the human acetylome 
To detect new potential HDAC6 substrates, we used our calibrated protocol 
(RLOOP_R) to screen the human acetylome (from PhosphoSitePlus[23]; we used only 
peptides annotated from low-throughput experiments) (Figure 4.4-A). This screen 
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detected around 242 and 600 peptides classified as substrates by our strict and non-strict 
cutoff (belonging to 141 and 257 proteins, respectively). Few (3) of these peptides score 
better than the top-scoring peptide in the D-TRAINING set. In comparison to our previous 
study on HDAC8 selectivity[9], many more potential substrates are suggested, which is 
in line with the reported significantly lower selectivity observed for HDAC6. 
We also compared the sequence logo created from these peptides to the one 
created from the training dataset (D-TRAINING), to ensure that we did not simply recreate 
the sequence specificity of that dataset (Figure 4.4-B,-C). Although there are some 
similarities, such as the preference for glycine at P-1 and for valine, tyrosine, and 
methionine at P+2, the sequence logo is different than the original database and has more 
variability. 
We selected 11 peptide analogs to measure activity with HDAC6 to test the 
robustness of our prediction model. 10 of the 11 selected peptides gave kcat/KM values 
over 10,000 M-1s-1, characterizing them as substrates by our criteria (Table 4.5, Figure 
4.5). One peptide did not meet the substrate cutoff, however, only a lower limit for the 
value of kcat/KM was determined so this peptide could be within substrate range as well.  
Since this was the lowest scored of the selected peptides, a stricter substrate cutoff of -
900 (which eliminated all false positives in the training set (Figure 4.3) could be more 
robust. Overall, the structure-based prediction model for zHDAC6 CD2 was able to predict 












Figure 4.4 : Application of the calibrated protocol (RLOOP_R) to the acetylome to detect novel potential 
HDAC6 substrates. 
(A) Distribution of scores obtained for acetylated peptides (as annotated in the Phosphosite database). 
The bin for the best scoring peptide in the training set is highlighted in blue, and the green arrows mark 
the threshold for discriminating substrates defined for RLOOP_R (-890 and -900 for non-strict and strict 
cutoff, respectively) (B-C) Sequence logos of (B) measured peptides (D-TRAINING set)  and (C) top 100 





Table 4.5: Kinetic parameters of selected predicted substrates from the human acetylome.  
Peptide 
















PC(K-Ac)EVD  NFAT5 (K282ac) -923.56 >10,000 0.22 ≤20 
PG(K-Ac)EEK  FOXM1 (K440ac) -914.77 >16,000 0.32 ≤20 
FP(K-Ac)EAK  EGFR (K1179ac) -913.74 >26,000 0.52 ± 0.02 <20 
IS(K-Ac)MND  IFI16 (K451ac) -911.69 >20,000 0.39 ± 0.02 <20 
KG(K-Ac)QAE  HMGN1 (K61ac) -909.3 14,000 ± 3,000 0.36 ± 0.04 26 ± 8 
HS(K-Ac)GFG  TARDBP (K145ac) -909.19 >45,000 0.9 ± 0.1 <20 
SG(K-Ac)GKK  GATA1 (K312ac) -908.68 >14,000 0.27 ± 0.03 <20 
AG(K-Ac)FGP  CGAS (K50ac) -905.59 >10,000 0.2 ± 0.1 <20 
QA(K-Ac)SPP  MEF2C (K239ac) -905.57 >35,000 0.7 ± 0.2 <20 
MG(K-Ac)GVS  ENO1 (K60ac) -905.4 >17,000 0.34 ± 0.09 <20 
NG(K-Ac)LTG GAPDH (K227ac) -897.7 >8,000 0.16 ± 0.06 <20 
aValues (mean ± standard error) were calculated using Equation 4.1 from initial velocities (n=4) from 4 substrate 
concentrations. 
 
Figure 4.5: Dependence of deacetylation rate on substrate concentration catalyzed by zHDAC6 CD2 for 
two representative peptides selected from the top acetylome hits. 
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Comparison of CD2 to CD12 substrate selectivity 
While we were able to create a model to predict substrates of HDAC6, it is based 
on a truncated form of the enzyme. The truncated form contains the catalytic domain, 
CD2, proposed to contain the deacetylase activity, but the other catalytic domain, CD1, 
likely serves some purpose in activity and potentially selectivity of HDAC6. We therefore 
explored the activity of a tandem construct, CD12, with a subset of the same peptides 
tested with CD2.  
When initially testing the CD12 construct, we found it was less active than CD2. 
The difference in activity was surprising as previous studies with both constructs found 
them to have similar activity[3]. An active site titration using the HDAC6-specific inhibitor 
Tubastatin A[27] was performed with CD12 to ensure accurate measurement of the 
concentration of active enzyme. Assuming a 1:1 binding of inhibitor to HDAC6, as 
inhibitors have been developed primarily for the CD2 domain[27], the titration indicated 
an active enzyme concentration comparable to the total concentration determined by 
absorbance at 280 nm (Figure 4.6).  
 
Figure 4.6: Active site titration of purified zHDAC6 CD12 with Tubastatin A 
The calculated x-intercept of when activity was completely inhibited was within error of the A280 calculated 




We additionally measured the activity with a substrate that has been previously 
tested with full-length zebrafish HDAC6 and full kinetic parameters have been 
published[28]. When tested with this substrate, Boc-Lys(Ac)-AMC, our value for kcat/KM 
was higher than the previously published number due to both increased in the kcat value  
and a decrease in the Km values (Table 4.6).  These comparisons suggest that our protein 
constructs have good activity and that the additional residues present in zHDAC6 CD12 
and full-length zHDAC6 lower the reactivity with peptide substrates.  
Table 4.6: Kinetic parameters obtained for various HDAC6 constructs with a Lys(Ac)-AMC substrate.  
Construct kcat/KM (M-1s-1) kcat(s-1) KM (M) 
zHDAC6 CD2a >150,000 3.7±0.6 <25 
zHDAC6 CD12a 30,000±10,000 0.49±0.07 20±10 
zHDAC6b 6,000±1,000 0.26±0.01 45±8 
akcat/kM values are presented as mean ± standard error, calculated from a saturation 
curve containing 4 substrate concentrations where the initial velocity was calculated 
from 4 timepoints. bThe values given for zHDAC6, a full-length construct, were taken 
from Miyake et al[28] for comparison to zHDAC6 CD12.  
We then proceeded to measure the activity of CD12 with peptide substrates 
previously tested with CD2 (Table 4.7). We measured the kinetic parameters for 
deacetylation of a total of 13 peptides catalyzed by CD12 and found that a majority of the 
peptides contained significantly different kinetic parameters than CD2 (Table 4.7). The 
kcat values for CD12 were lower than CD2 for 11 of the 13 peptides by 10-fold, on average. 
Furthermore, the KM values for 8 of the 13 peptides were lower for CD12 compared to 
CD2 and in many cases below the assay detection limit making it possible to only 
calculate lower limits for the value of kcat/KM. There were no peptides tested which had 




Table 4.7: Kinetic parameters of peptide substrates tested with zHDAC6 CD12 














KT(K-Ac)PIW HSP90A (K294ac) 6,000±5,000 0.10±0.02 20±20 
ME(K-Ac)KKE GBP7 (K389Ac) >2,000 0.06±0.03 <25 
MK(K-Ac)LKE PASD1 (K379ac) >2,000 0.06±0.04 <35 
KL(K-Ac)KKE MYH1 (K1085ac) >2,000 0.06±0.02 <25 
AM(K-Ac)HRS MYO1G (K90ac) >5,000 0.14±0.05 <25 
ME(K-Ac)FKI XPOT(K627ac) 350±50 >.15 >0.07 
YD(K-Ac)LRK ACTN4 (K214ac); TUBG1 (K397ac) 5,000±4,000 0.16±0.08 30±40 
ID(K-Ac)RTI EEF1A1 (K31ac), EEF1A2, 
EEF1A1P5 (K36ac) 2,000±1,000 0.15±0.07 70±60 
EV(K-Ac)KMT MAP4 (K847ac) 600±400 0.1±0.1 200±300 
QK(K-Ac)VKE ZNF280D (K209ac) >2,000 0.047±0.004 <25 
AG(K-Ac)RIA DIP2A (K50ac) >6,000 0.09±0.06 <15 
QD(K-Ac)PLR CCDC86 (K261Ac) >2,000 0.1±0.1 <25 
QG(K-Ac)SGN MYO18B (K401ac) 10,000±4,000 0.15±0.02 15±8 
aValues (mean ± standard error) were calculated from saturation curves constructed from initial velocities (n=4) of at 





Figure 4.7: Dependence of deacetylation rate on substrate concentration for two representative peptides 






We have successfully produced a structure-based model to predict HDAC6 
substrates. However, the increased activity and promiscuity of HDAC6 made this process 
more difficult than for the previous HDAC isozyme studied, HDAC8. We randomly 
selected the peptides in the training set with high sequence variability, yet only a small 
fraction (7 out of 50) was characterized as non-substrates. Furthermore, the difference in 
activity between a substrate and non-substrate was smaller than what was previously 
seen with HDAC8, where the difference was over four orders of magnitude compared to 
the two orders of magnitude seen for HDAC6. A consequence of the condensed area of 
peptide activity is that good correlations are more difficult to obtain. By recognizing and 
utilizing structural differences between the isozymes, we were able to build a model with 
a correlation above 0.5.   
Structural differences dictate substrate binding specificity 
For HDAC8 we were able to obtain good predictions without introducing any 
backbone receptor flexibility[9]. Comparison of the HDAC6 and HDAC8 structures 
highlighted two main differences in the loops forming the binding pocket that could lead 
to differences in binding selectivity. First, the loop with the residue that forms a hydrogen 
bond and positions the substrate’s acetylated lysine, D101 in HDAC8 and S531 in 
HDAC6, contact the substrate at a similar position, but stem from a very different loop 
structure (Figure 4.2). This loop participates in the formation of the pocket 
accommodating the residue preceding the acetylated lysine (P-1). In HDAC6 this pocket 
is considerably smaller, explaining the significant enrichment for glycine at P-1. Second, 
the loop located near the pocket that accommodates the residues C-terminal to the 
 
119 
acetylated lysine (P+1) is significantly longer in HDAC6 (12 residues compared to 7 in 
HDAC8) and more hydrophobic. The larger size of the loop, together with its more 
nonpolar character, suggest that this HDAC6 loop may be more flexible, allowing for 
adaptations of the binding groove resulting in a more promiscuous binding pattern. We 
showed here that this loop needs to move for our protocol to succeed, suggesting that 
this pocket opens for substrate binding.  
We additionally demonstrated that the second catalytic domain (CD1), present in 
a more full-length construct of HDAC6, effects catalytic activity and selectivity of CD12. 
When evaluating the small number of sequences of peptides which had similar activities 
for CD2 and CD12, there is a preference for lysine residues at P-2, P+1, and P+2 and for 
glutamate at P+3 (Figure 4.8-B). Sequences of peptides where CD2 activity was greater 
than CD12 do not follow any striking residue preferences, with only a slight preference 
for lysine at P+2 (Figure 4.8-A).  These differences suggest structural differences between 
CD12 versus CD2 in binding substrates. However, the crystal structures of full-length 
zHDAC6 and CD2 do not show any significant structural differences (Figure 4.8-C). 
There is a slight perturbation of the loop which accommodates the C-terminal peptide 
residues, which perhaps limits the amount of loop opening seen as necessary for 
modeling the promiscuity of CD2. Sampling of yet more loop structures, prior or together 
with the peptide structure optimization, can in the future pave the way for application of 
this approach to more flexible receptors, provided proper calibration is applied to focus 











Figure 4.8: Structural differences between zHDAC6 CD2 and CD12. 
A) Sequence logo of peptides which display greater activity with CD2 than CD12. B) Sequence logo of 
peptides which display similar activity with CD2 and CD12. C) Overlay of CD2 (green/orange) and 




Structure-based model can predict novel HDAC6 substrates 
The proposed model seems to be especially suited to confidently predicting good 
substrates of HDAC6. When the model was applied to the known acetylome, over 300 
sites were identified below the substrate cutoff of -890. The proteins belonging to the top 
100 best scoring peptides (see Appendix) were submitted to Reactome Pathway 
analysis[29] to identify the likely pathways they are involved in. Using this analysis we 
identified several pathways which have been previously reported to be linked to HDAC6, 
such as autophagy and aggrephagy[30], transcriptional regulation by TP53 [31], NOTCH1 
signaling[32, 33], EGFR signaling[34, 35], MAPK signaling[36], and cytosolic sensors of 
pathogen-associated DNA[37, 38]. It is encouraging that our protocol can confirm HDAC6 
involvement in these pathways.  
To further test our protocol’s reliability, we determined HDAC6 activity with 11 
predicted substrate peptides. HDAC6 demonstrated catalytic efficiency above the 
substrate cutoff for almost all the peptides (10 out of 11). Only two of these substrates, 
epidermal growth factor receptor (EGFR) and TAR DNA-binding protein 43 (TDP43), 
have previously been explored as direct substrates of HDAC6[34, 35, 39, 40]. The other 
proteins for whom peptide analogs were tested represent novel potential substrates of 
HDAC6. A few of these proteins have identified interactions with HDAC6: nuclear factor 
of activated T-cells 5 (NFAT5 [41]), alpha enolase (ENO1 [42]), and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH [42]). The misregulation of several predicted 
substrates, ENO1, a tumor associated antigen[43], GAPDH, regulator of cell death[44], 
and forkhead box protein M1 (FOXM1), a transcription factor responsible for cell 
proliferation[45], has been implicated in cancer phenotypes. HDAC6 activity is further 
 
122 
connected to the immune response with the potential substrates of: non-histone 
chromosomal protein HMG-14 (HMGN1), an alarmin which triggers the innate and 
adaptive immune response[46]; gamma-interferon-inducible protein 16 (IFI16), which 
triggers host response to viral DNA[47]; and cycle GMP-AMP synthase (CGAS), a 
cytosolic DNA sensor[48]. New roles for HDAC6 could potentially be found in the 
acetylation of NFAT5[41] and MEF2C[49], transcription factors important for muscle cell 
development, and GATA1, an important transcription factor in blood cells whose 
acetylation promotes bromodomain binding to chromatin[50]. The predicted substrates 
are diverse, yet most fit within functions previously linked to HDAC6, immunity[37, 51, 52] 
and cancer[53, 54], but this analysis also identified some potential novel roles of HDAC6 
in muscle and blood cell development.  
The successful construction of a structure-based model for another HDAC isozyme 
indicates the positive ability of utilizing this method to predict novel substrates. There have 
been several methods used to predict HDAC substrates including in vivo inhibition[55] 
and substrate-trapping pulldown methods including photo-crosslinking[25] and mutant 
capture[56]. While these methods take advantage of the enzymes in their natural, 
biologically relevant state, data analysis is more cumbersome, and the number of 
substrates identified is limited (≤100). Using a computational model allows the screening 
all known acetylated proteins upfront with less effort, where identified substrates can then 
be followed up on in more detailed, specific analysis. Structure-based modelling is not 
without its limitations, as it is dependent on substrate selectivity being predicted at the 
local sequence level, which was challenging and somewhat lacking for HDAC6 in 
comparison to HDAC8. Even with these limitations, using the prediction model was 
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illuminating for discovering novel substrates and novel avenues of substrate exploration 
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Chapter 5 : Conclusions and Future Directions 
 
Regulation of HDACs is multi-faceted 
My thesis has explored regulation of HDACs by probing several variables, namely: 
identity of the active site metal, post-translational modifications, and complex formation. 
It is known in the field that these variables play key roles in regulation, but there is limited 
information about how they affect HDAC deacetylase activity. My research has 
contributed to the growing knowledge of these regulatory measures and will provide 
insights into new directions of research into HDACs.  
Identity of in vivo active site metal 
The field at large has not explored the identity of the in vivo active site metal of 
HDACs. The prevailing view is that HDACs are Zn(II)-dependent deacetylases.  No 
significant structural differences between HDAC8 with reconstituted metals have been 
observed[1]. However, there have been continued examples of varied deacetylase 
activity and selectivity between the different reconstituted forms[2, 3], which indicates 
metal identity is changing some aspect of enzyme catalysis. My exploration of metal 
specific inhibitors detailed in Chapter 2 illustrates that there are significant differences in 
ligand affinity depending on the active site metal ion, corroborating the previous studies 
demonstrating the differing selectivity of the different reconstituted forms of HDAC8.  
With evidence of these differences, it would be interesting to explore what aspects 




been determined for HDAC8-Zn(II) and HDAC8-Fe(II), where HDAC8-Zn(II) has a higher 
kcat (about 2-fold) but also has a larger KM (about 5-fold)[3]. A smaller KM for HDAC8-
Fe(II) could indicate a structure that is more conducive for substrate binding. It has 
previously been proposed Fe(II) and Co(II) form a stronger interaction with the acetylated 
substrate than Zn(II) leading to the observed activity differences and the lower KM values 
for both HDAC8-Fe(II) and HDAC8-Co(II)[3]. This would seem to indicate similar structure 
between HDAC8-Fe(II) and HDAC8-Co(II), though that contradicts what I observed with 
the metal-specific inhibitors in Chapter 2 as the metal-specific inhibitors were unable to 
inhibit HDAC8-Co(II). However, only having this detailed kinetic information for one 
peptide limits our ability to make conclusions. It would be useful to know if this trend also 
depends on substrate sequence, but only overall catalytic efficiency (kcat/KM) has been 
determined for unlabeled peptides[2] due to lower activity and higher KM values, so it is 
unknown if the trend is generalizable to HDAC8 kinetics. Ideally, a crystal structure of 
HDAC8-Fe(II) bound to a Fe(II)-specific inhibitor or structures of unliganded different 
metalloforms would visualize the structural differences and how these changes relate to 
substrate affinity and reactivity.  
To validate the importance of HDAC8-Fe(II), an in vivo connection needs to be 
demonstrated. The cellular concentrations of the two metal ions are comparable to their 
binding affinities to HDAC8[4-7] , so switching between the two metals could be used as 
a regulatory mechanism that alters both activity and selectivity. This has been a difficult 
area to research as the endogenous expression levels of HDAC8 are too low to provide 
an adequate amount of metal-bound enzyme to accurately measure the metal identity by 




mainly the tight-binding Zn(II) (unpublished data from Fierke lab). It is possible that the 
preference for Zn(II) when HDAC8 is overexpressed could be due to Fe(II) being highly 
regulated in cells with insufficient Fe(II) for the additional protein[6].   
A different way to examine if HDAC8 is regulated by Fe(II) and Zn(II) is by exploring 
the regulation of HDACs in cells. HDAC8-Fe(II) would be sensitive to reactive oxygen 
species, so HDAC activity and selectivity would change based on cellular environment. I 
demonstrated in Chapter 2 that HDAC activity is cell lysates is oxygen sensitive, and 
HDAC activity has been connected to hypoxic conditions through regulation of hypoxia-
inducible factor 1[8-10]. Though the oxygen sensitivity of HDACs has also been 
connected to redox sensitive residues in several members of the HDAC family where 
oxidation of these residues inhibits deacetylase activity, it has not been explored if this 
oxidation changes both activity and selectivity.  
The lack of clarity indicates further studies need to be conducted to determine if 
the identity of the active site metal is a component of in vivo regulation of HDACs. Thus 
far, the primary studies have been performed with HDAC8 but perhaps further studies 
with other HDAC isozymes such as HDAC6 and HDAC1 could help elucidate if this 
possibility of metal switching is specific to HDAC8 or pertains to the whole enzyme family. 
One way to start exploring this area is to prepare apo-HDAC6 and apo-HDAC1 and use 
the identified metal-specific inhibitors with different reconstituted forms of HDAC6 and 
HDAC1 to see if the ligand affinity and catalytic activity are also dependent on the active 




Post-translational modifications  
HDACs themselves have been found to be subject to modifications as knowledge 
of acetylation and other post-translational modifications has expanded across the 
proteome. Among the HDACs I have discussed within my thesis, phosphorylation has 
been the only PTM studied as important for regulating the activity of HDAC6 and HDAC8 
(confirmed by low-throughput experiments). I demonstrated that HDAC1 phosphorylation 
is important for both activity and selectivity. No doubt other PTMs regulate selectivity of 
HDAC1, as several other PTMs, such as acetylation and sumoylation, have been 
observed.  
 In Chapter 3 I explored two phosphorylation sites, Ser421 and Ser423, which are 
known to be important for activating deacetylase activity[11]. Two additional, less studied, 
phosphorylation sites, Ser406 and Ser393, are located outside of the deacetylase domain 
of HDAC1 (Figure 5.1). Phosphorylation of Ser393 has shown to increase deacetylase 
activity[12]. Phosphorylation of Ser406 occurs in early mitotic cells from prophase to 
metaphase, but the effect of this PTM is not known[13]. All of these phosphorylation sites 
exist within a 30-residue section of HDAC1 potentially making this region an important 
regulatory component of HDAC1 activity.  
Acetylation has additionally been recently explored on HDAC1. Contrary to 
phosphorylation, acetylation inhibits deacetylase activity and induces association with the 
glucocorticoid receptor in response to hormone stimulation[14]. There are numerous 
potential acetylation sites: K218, K220, K432, K438, K439, and K441[14]. Two of these 




remaining sites are located not far from the proposed phosphorylation sites, further 
indicating that this region of HDAC1 is an important for cellular regulation via PTMs. 
The final PTM sites identified in HDAC1 are K444 and K476 which are sumoylated.  
Sumoylation at these sites is known to regulate HDAC1’s biological functions, but 
unknown to what degree[15], and has been found to be important in reducing amyloid 
plaques[16].  
The effects of these different PTMs on activity can be determined by generating 
the in vivo PTMs in vitro. Non-canonical amino acid incorporation can be utilized to study 
the effects of these post-translational modifications. Incorporation of non-canonical amino 
acids (NCAA) in recombinant proteins has advanced in the last 10 years to a point where 
high fidelity and yield can be accomplished[17-23]. E.coli is still the easiest organism to 
achieve NCAA incorporation[24] and I have shown in Chapter 3 HDAC1 expressed in 
E.coli can recapitulate the activity of mammalian and insect expressed enzyme. Analogs 
of phosphoserine and acetylated lysine have been successfully incorporated into 
expressed proteins[25, 26]. NCAA incorporation cannot be used for sumoylation, as it is 
a protein, but due to the similarity to ubiquination, sumoylation has been achieved by in 
vitro assays[27]. 
 
Figure 5.1: The proposed post-translational modifications of HDAC1. 
The sites are denoted by lines, colored by modifications (see Legend). The conserved deacetylase 





It is curious that regulatory post-translational modifications are concentrated within 
the C-terminal region of HDAC1 rather than in the conserved deacetylase domain (Figure 
5.1). Therefore, HDAC1 can be separated into a deacetylase domain and a regulatory 
domain; other members of the deacetylase family may also follow this division. As I have 
shown in Chapter 3, phosphorylation of HDAC1 on Ser421 and Ser423 affects the activity 
and selectivity of HDAC1 but does not clearly stimulate protein-protein interactions. An 
exploration of the effects of potential PTM sites on activity and complex formation as well 
as whether these PTMs co-exist or have any synergistic effects are important future 
questions.  
Complex Formation 
My work described in Chapter 3 demonstrates that complex formation between 
HDAC1 and other proteins has an enormous effect on activity. This work only explored 
interactions with two other proteins, a small fraction of the protein interactions that have 
been identified with HDAC1 (~600 proteins[28, 29]). Furthermore, this work was on a 
known stable complex. There have only been 3 such complexes identified for HDAC1, 
leaving hundreds of other interactions that could have similar effects on activity.  
 These interactions are typically explored by in vivo experimentation or co-
purification of the entire complex. My work has illustrated that in vitro reconstitution and 
activity assays can also be effective in evaluating the effects of protein-protein 
interactions. Using in vitro reconstitution additionally allows for more flexibility in building 
up these interactions to study their individual and combined effects. For HDAC1 the 
method of building up interactions is particularly useful because the known stable 




are many additional interacting proteins that could affect activity and selectivity. For the 
CoREST complex, LSD1 and CoREST both share an additional 8 interacting proteins 
with HDAC1 (determined from BioGRID[28, 29]). The interaction networks of LSD1 and 
CoREST with HDAC1 show even more potential interactors (Figure 5.2), which opens 
numerous questions as to how this complex in regulated within cells.  
 
Figure 5.2: Overlapping interactions between HDAC1 and CoREST (RCOR1) or LSD1 (KDMA1). 
A) The blue circles indicate interactors of both LSD1 (KDMA1, in green) and HDAC1 (in maroon). B) The 
blue circles indicate interactors of both CoREST (RCOR1, in green) and HDAC1 (in maroon). Obtained 
from BioGRID[28, 29].  
 
 In future studies it would be very interesting to explore potential protein interactors 
with HDAC6 and HDAC8. Both of these HDACs have more limited identified potential 
interactions, as indicated by co-immunoprecipitation experiments[30]. For HDAC8 the 
most concretely identified interactor with HDAC8 is structural maintenance of 
chromosomes protein 3 (SMC3)[30] which is also a substrate[31-33]. In addition to SMC3, 
HDAC8 has been connected to other proteins involved in the cell cycle and cell 
division[30]. Interactions with HDAC8 are also proposed with cytoskeleton associated 




interactions, it is not clear whether they are HDAC8 substrates or if they regulate HDAC8 
activity.  
 HDAC6 uniquely contains a ubiquitin binding domain, so it is no surprise that there 
are numerous interactions with ubiquitin-containing proteins[30].  HDAC6 has also been 
shown to interact with dynein to shuttle proteins to aggresomes[34]. It is unknown how or 
whether the deacetylase activity of HDAC6 is involved in these interactions, though 
catalytically inactive mutants are not as effective as wild-type enzyme in regulating 
aggresome formation[34].   
Regulatory mechanisms alter selectivity rather than just activity 
 Commonly regulatory measures either activate or inactive enzymatic activity. 
Recent studies have demonstrated that regulation of HDACs is more complicated since 
these regulatory modifications may also impact selectivity, not just activity. The impact on 
selectivity highlights the need to identify the most likely cellular substrates of these 
enzymes. The knowledge of isozyme-specific substrates will be crucial for understanding 
how changes in selectivity due to regulatory modifications will affect the implicated 
biological pathways.  
 The Fierke lab had previously collaborated with Prof. Ora Furman-Schueler’s 
group at Hebrew University of Jerusalem to create a very successful model of HDAC8 
selectivity[35]. In Chapter 4, I discussed the continued use of structure-based modeling 
to assist in discovering novel HDAC substrates as we applied this method to a second 
HDAC, HDAC6.  It became apparent that HDAC6, at least the single CD2 domain of 
HDAC6, does not contain as much substrate selectivity at the sequence level as HDAC8. 




construct to determine if the lack of selectivity is mediated by structural changes induced 
by the presence of the other catalytic domain. I began exploring these selectivity 
differences in Chapter 4 and saw that the presence of both domains changes the 
selectivity of HDAC6.  However, with a limited sample size it is difficult to ascertain how 
selectivity changed. Additional attempts to elucidate the substrate selectivity of HDAC6 
reinforce the promiscuity previously seen; when HDAC1, HDAC3, HDAC6, and HDAC8 
were screened against a diverse 3-mer coumarin labeled peptide library, it was found that 
HDAC6 has the broadest selectivity of all the isozymes[36]. A limitation of these studies 
was that peptide substrate analogs are used. The peptides are unable to mimic any 
contacts the full structure of the substrate might form outside the active site. These 
additional contacts were shown to be important with HDAC1 in Chapter 3.  
 The lack of sequence level selectivity suggests that other factors play a role in 
determining the substrate selectivity of HDAC6, and potentially other HDAC isozymes. 
The external signaling factors that could dictate HDAC activity include active site metal 
identity, post-translational modifications, and protein interactions. Measures to determine 
how each of these factors affect certain HDACs can be achieved by utilizing the methods 
of site-directed mutagenesis and NCAA incorporation, apo-enzyme purification with metal 
reconstitution, and complex co-purification or immunoprecipitation.  
The future of HDAC research 
 Based on the body of work presented in this thesis I believe the future of HDAC 
research should focus in the following areas: substrate discovery, in vitro analysis 




build a complete picture of the biological impacts of HDAC deacetylase activity and 
targeting this activity to treat and prevent disease.  
 One of the most important foci of HDAC research should be on substrate 
discovery. As illustrated within this thesis, we are slowly building an understanding of how 
substrate selectivity is determined by HDAC but there is still a long way to go before we 
truly understand what is happening within the cell. There are very few confirmed 
substrates for any of the HDAC isozymes within the tens of thousands of acetylation sites 
identified within the human proteome. There have been multiple substrate discovery 
methods utilized, each with their own positives and limitations. Further refinement of these 
substrate discovery methods to incorporate important factors that determine selectivity 
will be essential for a complete isozyme-specific substrate list to be determined.  
 In vitro analysis of the activity and selectivity of HDAC enzymes can be used to 
identify the most important selectivity factors. HDACs will need to be screened against 
peptide substrates with and without potentially important selectivity factors (i.e. post-
translational modifications, other interacting proteins). It is additionally necessary that the 
in vitro and in vivo analyses work together to test and confirm results to provide the best 
analysis of substrate selectivity. 
 Finally, with all the information gained from substrate selectivity and regulatory 
factors I believe the field will be able to identify inhibitors that lead to better patient 
outcomes. There are only currently 4 FDA-approved HDAC inhibitors, and the majority of 
HDAC inhibitors that enter clinical trials fail. In a study of the clinical trials between 2013 
and 2017 only 1% reached Phase 4[37]. The failure rate could be due to not 




the inhibition of the enzymes cannot be well predicted. The continued development of 
isozyme-specific inhibitors along with non-hydroxamate inhibitors will lead to more 
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protein Gene Protein name modsite 




Nuclear factor of activated T-
cells 5 
K282-ac 
STKEVD -923.014 1 Q9H4B7 TUBB1 Tubulin beta-1 chain K324-ac 
NSKQPA -917.96 1 P20248 CCNA2 Cyclin-A2 K95-ac 
MSKEQF -915.87 1 Q16236 NFE2L2 
Nuclear factor erythroid 2-
related factor 2 
K487-ac 
PGKEEK -914.77 1 Q08050 FOXM1 Forkhead box protein M1 K440-ac 
AGKQLR -914.17 1 Q8NC51 SERBP1 
Plasminogen activator 
inhibitor 1 RNA-binding 
protein 
K68-ac 
FPKEAK -913.741 1 P00533 EGFR 








AGKFKR -913.02 1 P39748 FEN1 Flap endonuclease 1 K375-ac 
ASKESH -912.884 1 P40763 STAT3 
Signal transducer and 
activator of transcription 3 
K49-ac 
NDKEAA -912.30 1 P27695 APEX1 
DNA-(apurinic or apyrimidinic 
site) endonuclease 
K35-ac 









SKKDPE -911.311 1 P19838 NFKB1 






KNKEQH -910.88 1 O60934 NBN Nibrin K504-ac 
YSKQMQ -910.82 1 Q92769 HDAC2 Histone deacetylase 2 K90-ac 
LNKEMV -910.753 1 Q8NEB9 PIK3C3 
Phosphatidylinositol 3-kinase 
catalytic subunit type 3 
K781-ac 





GPKGIG -910.59 1 P50461 CSRP3 
Cysteine and glycine-rich 
protein 3 
K69-ac 
TSKAVS -910.47 1 P29590 PML Protein PML K515-ac 
GSKNVD -910.36 1 O60934 NBN Nibrin K208-ac 












KKKEFE -909.28 1 O15392 BIRC5 
Baculoviral IAP repeat-
containing protein 5 
K122-ac 
KAKDPT -909.232 1 Q00613 HSF1 Heat shock factor protein 1 K524-ac 
HSKGFG -909.19 1 Q13148 TARDBP TAR DNA-binding protein 43 K145-ac 
PAKFPS -909.17 1 P17482 HOXB9 Homeobox protein Hox-B9 K27-ac 
GVKSPG -909.03 1 Q01094 E2F1 Transcription factor E2F1 K120-ac 
SGKSAK -908.95 1 Q13569 TDG 
G/T mismatch-specific 
thymine DNA glycosylase 
K87-ac 
GSKQNS -908.80 1 P29084 GTF2E2 
Transcription initiation factor 
IIE subunit beta 
K52-ac 
KEKEMN -908.76 1 Q9NR30 DDX21 Nucleolar RNA helicase 2 K137-ac 
SGKGKK -908.68 1 P15976 GATA1 Erythroid transcription factor K312-ac 








NSKSVP -908.18 1 O60563 CCNT1 Cyclin-T1 K380-ac 
LNKSPP -908.15 1 Q01543 FLI1 
Friend leukemia integration 1 
transcription factor 
K240-ac 
PGKALV -907.94 1 P19338 NCL Nucleolin K116-ac 
PIKEDS -907.751 1 P00533 EGFR 




NGKEQL -907.70 1 Q8NHS0 DNAJB8 
DnaJ homolog subfamily B 
member 8 
K223-ac 
TAKAVD -907.675 1 P51692 STAT5B 
Signal transducer and 
activator of transcription 5B 
K694-ac 
VGKEPS -907.66 1 O94925 GLS 
Glutaminase kidney isoform, 
mitochondrial 
K311-ac 
KDKRNQ -907.54 1 P41235 HNF4A 
Hepatocyte nuclear factor 4-
alpha 
K108-ac 
KGKGKG -907.30 3   COL Collagen   
PSKLDS -907.145 1 P07900 HSP90AA1 
Heat shock protein HSP 90-
alpha 
K69-ac 
SGKAKT -907.13 1 P0C0S5 H2AZ1 Histone H2A.Z K11-ac 
SGKGNP -907.10 1 P35222 CTNNB1 Catenin beta-1 K49-ac 





YGKLPP -907.05 1 Q9Y2D1 ATF5 
Cyclic AMP-dependent 
transcription factor ATF-5 
K29-ac 
MKKEMI -907.03 1 O75469 NR1I2 
Nuclear receptor subfamily 1 
group I member 2 
K109-ac 
NVKAKI -906.88 1 P62988 UBB 
Polyubiquitin-B [Cleaved into: 
Ubiquitin] 
K27-ac 










GAKFPI -906.799 1 P12931 SRC 
Proto-oncogene tyrosine-









LNKEKK -906.75 1 P14316 IRF2 Interferon regulatory factor 2 K29-ac 
ADKDYS -906.56 1 P07195 LDHB 
L-lactate dehydrogenase B 
chain 
K82-ac 
NGKGRP -906.51 1 P15923 TCF3 Transcription factor E2-alpha K34-ac 
TRKEME -906.47 1 P42858 HTT Huntingtin K343-ac 
AEKQRP -906.42 1 Q96EP5 DAZAP1 DAZ-associated protein 1 K150-ac 





ALKAPS -906.23 1 O60566 BUB1B 
Mitotic checkpoint 
serine/threonine-protein 
kinase BUB1 beta 
K250-ac 
SAKGFG -906.10 1 Q99814 EPAS1 
Endothelial PAS domain-
containing protein 1 
K685-ac 
FTKDKH -906.04 1 Q16236 NFE2L2 
Nuclear factor erythroid 2-
related factor 2 
K443-ac 





CDKEYV -905.94 1 O43623 SNAI2 Zinc finger protein SNAI2 K166-ac 




FSKEAS -905.86 1 Q9P0J1 PDP1 
[Pyruvate dehydrogenase 
[acetyl-transferring]]-
phosphatase 1, mitochondrial 
K202-ac 
RSKEIT -905.84 1 P17844 DDX5 
Probable ATP-dependent 
RNA helicase DDX5 
K80-ac 
KPKAPL -905.84 1 O95600 KLF8 Krueppel-like factor 8 K95-ac 
GGKAGK -905.83 1 P0C0S5 H2AZ1 Histone H2A.Z K4-ac 
GTKAVT -905.78 1 P33778 H2BC3 Histone H2B type 1-B K116-ac 

















MGKGDP -905.66 2   HGB High mobility group protein   
FGKIIR -905.60 1 P49773 HINT1 
Histidine triad nucleotide-
binding protein 1 
K21-ac 
AGKFGP -905.59 1 Q8N884 CGAS Cyclic GMP-AMP synthase K50-ac 




MGKGVS -905.40 1 P06733 ENO1 Alpha-enolase K60-ac 
AGKGKY -905.37 1 Q13547 HDAC1 Histone deacetylase 1 K218-ac 













MSKQEL -905.00 1 O94992 HEXIM1 Protein HEXIM1 K284-ac 
KGKYYA -904.97 1 Q13547 HDAC1 Histone deacetylase 1 K220-ac 
NAKQHK -904.96 1 O60934 NBN Nibrin K233-ac 








AGKQLE -904.84 1 P62988 UBB 
Polyubiquitin-B [Cleaved into: 
Ubiquitin] 
K48-ac 
GGKARA -904.77 2   H Histone   
PRKEPV -904.68 1 P26358 DNMT1 DNA K961-ac 









NGKDSK -904.60 1 P06748 NPM1 Nucleophosmin K212-ac 
ANSFVG -904.539 1 P36507 MAP2K2 
Dual specificity mitogen-
activated protein kinase 
kinase 2 
S226-ac 
PSKSAP -904.45 1 P33778 H2BC3 Histone H2B type 1-B K5-ac 
PSKSVL -904.33 1 Q08050 FOXM1 Forkhead box protein M1 K614-ac 
LNKNMQ -904.327 1 Q06413 MEF2C 
Myocyte-specific enhancer 
factor 2C 
K234-ac 
 
